


Res,



"We stand by life"





"We stand by life"

There are some works, some people those who just focus on success. They neither talk about themselves nor care about announcing their names written in capital letters. Their happiness is their success. Along with awards, their success is the happiness that is created by people's thanks to their services and products. Even if you don't notice, their focused efforts and created products have added value to your life. With aims to works, not to the talks, they make differences by contributing to our basic needs of life like in health.

Polifarma, which has been working in accordance with this principle as of its establishment and always improves itself in the field of health sciences and health technologies, and is the most well-known brand in hospital products in Turkey, always focuses on "life". With its existence, this focal point covers nature, living things and every detail which provide that inhabits in life. Because every detail that makes life livable brings along a healthier world. The quality of life, which we prioritized on our way with the aim of a healthier world, brought us together with the concept of "We stand by life". With the concept of we stand by life, we have adopted the continuously learning, quality understanding of our employees in our services; as a company that uses all its resources effectively, we have become a constantly developing brand that offers the best and quality health services under the light of practices, and research. Because "We stand by life" is a responsibility that is proud to say also it requires effort and dedication. With our perspective that adheres to ethical values, respects the right to life and prioritizes human health, we continue to touch life and provide reliable service at international standards with trust and health wherever we call "We stand by life".

As Polifarma, we are proud of having nearly 600 licensed products, 8 awards in 15 therapeutic areas, 12 certificates, an annual production of 350 million boxes, more than 1350 employees and 100% domestic capital. Being the world's first and only CAPD device developer, Turkey's first domestic 3-chamber parenteral nutrition solution manufacturer, obtaining Turkey's first rapid and Raman spectroscopy quantitative test approval, being the first intravenous NK-1 blocker

manufacturer of our country and first domestic plasma volume expander manufacturer are the result of our main object. Being the best known and most preferred brand in hospital products in Turkey is not only a success for us, rather it is a milestone towards the success goal which we aim in the global market.



## OUR VISION

As the domestic hospital products leader who combines and implements its strong experience, our vision is to become one of the global player by the year 2025.

## OUR MISSION

We undertake to produce the most reliable hospital products and to be transparent to the whole society. We work with the same passion every day to offer the best quality of life with products that we produce with the highest health standards and being environmentally friendly. With our culture which is dedicated to save and sustain lives, we touch the lives of patients, healthcare professionals, the community, and other stakeholders around the world.








## OUR PRODUCTION FACILITY AND OFFICES

Our headquarters was established in Istanbul in 1986 and our serum production continued at our facility in Çatalca till the end of 2010. In 2011, Ergene Production facility has started operating.

In this process, our production, which started with glass forms, continued with the production of PVC bags, PP Bags (The first Polypropylene bag investment in Turkey) and the development of the product range, as well as the production of parenteral solutions. With a wide range of products, our organization has become the leading supplier of all healthcare institutions in the country.



#### **Production Facility**

Vakıflar OSB Mah. Sanayi Cad. No: 22/1 P.K.:59930 Ergene / Tekirdağ Telephone: 0282 675 14 04 Fax: 0282 675 14 05 E-Mail: info@polifarma.com.tr

#### **Headquarters**

Halkali Merkez Mah. Basin Ekspres Cad. Capital Tower İş Merkezi, No: 9 Kat: 6 Halkalı Küçükçekmece / Istanbul PK:34259 Telephone: 0212 481 00 13 Fax: 0212 481 00 73 E-mail: info@polifarma.com.tr

#### **Regulatory Center**


312 VISTA Eskişehir Yolu 2176. Cadde No: 9 Kat: 7 Ofis No: 14 Söğütözü – ANKARA / TÜRKİYE Telephone: 0312 287 18 89 Fax: 0312 287 64 49 E-mail: info@polifarma.com.tr



## OUR PRODUCTION CAPACITY

We are a global brand with our production facility having 10 different production areas with annual 350 million unit capacity in 55.000 square meter indoor and 1.740 square meters aseptic production. Besides manufacturing ampoules, vials and PFS, we have nearly 600 licenced products in all forms, with 8 awards and 12 certificates in 15 therapeutic areas.

## A POLIFARMA





## OUR QUALITY POLICY

Our quality understanding as the only domestic manufacturer among the companies producing 10 different packaging forms for Large Volume Parenteral, Small Volume Parenteral, Nutritional Solution and Veterinary products in the Turkish pharma industry:

We aim to provide service to human health as experts in their field by following the regulations that must be complied with within the scope of ISO 9001/13485, by using modern technology in accordance with Current Good Manufacturing Practices (c-GMP) established under the leadership of the World Health Organization and supported by Republic of Turkey Ministry of Health.

With the awareness that there can be no second-class quality in health, we follow all current practices and we follow all current practices and aim to produce and sell the serums injected intravenously (I.V) to patients under the determined standard conditions. Thanks to our EU-GMP (good manufacturing practices), we continue to work by registering our production quality in international standards.

We see our understanding of quality as a part of our corporate culture to provide convenience in terms of patient use, and we see continuous development and increasing the product range as a principle.

To achieve our goals, we continuously improve our quality management system with our life learner human resources.

In the process of delivering the product from the raw material input to the final consumer during the preparation of product, it implements an effective quality system. Providing customer satisfaction by adopting a human-oriented production vision with system monitoring is among the priorities of our company.





## POL R&D

Polifarma's R&D center POL R&D, ranked one of the most R&D investors and one of the top companies carrying out the most projects. Developed by our POL R&D team based on a statistical product development approach, we offer Turkey's first lipid products; Polinuthree, Propofol-PF, BFS and Anesthesia Gas Project.

These are the products we innovated for every single human in our world.

Particularly, the Anesthesia Gas Project is a product in gas form, and it is a drug for which the entire production process is managed by using enclosed systems from the production phase to the packaging phase. The substances contained in the gas have been analyzed by using the devices capable of measuring with one in a million precision, and have been proven to provide the purest product, and the entire process has been taken under control. We are proud of being the first domestic manufacturer in Turkey to manufacture the "Anesthesia Gas" products on the isolated production equipment by our personnel that wear special respiratory systems clothes at our production areas equipped by the high standards of ventilation systems.

Our goal is to create a global R&D center by combining our knowledge and expertise and to become a leading company in innovative drug development studies.



## POL R&D AWARDS AND ACHIEVEMENTS

Our POL R&D team;

has successfully completed more than 50 The Scientific and Technological Research Council of Turkey (TUBITAK) projects, It has more than 50 patents registered with the European Patent Office, It has developed over 700 generic drugs with over 20 years of R&D experience, It has presented more than 500 drugs to the pharma industry in Turkey, more than 40 drugs in the European Union countries and the USA.





## OUR EXPORT TO ALL OVER THE WORLD CONTINUES WITH A PROGRESSIVE DEVELOPMENT EVERY SINGLE DAY





## SMALL VOLUME PARENTERALS

ACTIVE INGREDIENT	THERAPEUTIC FIELD	PAGE
Anidula fungin	Antifungal	1
Ascorbic Acid (Vitamin C)	Vitamin C Deficiency	1
Acetylcysteine	Mucolitic, Asetaminofen Antidote	1
Acyclovir	Antiviral	1
Bupivacaine HCl	Local Anesthetic	1
Calcitriol	Vitamin D Analogue	2
Caspofungin Acetate	Antifungal	2
Ciprofloxacin Lactate	Antibacterial	2
Colistimethate Sodium	Antibacterial	3
Dexmedetomidine HCL	Sedative & Hypnotic	3
Dobutamine Hydrochloride	Cardiac Stimulant	4
Enoxaparin Sodium	Low Moleculer Weight Heparin	4
Esmolol Hydrochloride	Supraventricular Tachycardia and	_
	Hypertension Treatment	5
Esomeprazole Sodium	Proton Pump Inhibitor	5
Fentanyl Citrate	Opioid Analgesics	5
Fluconazole	Antifungal	6
Flumazenil	Benzodiazepine Antidote	6
Fluorescein Sodium	Imaging Agent	7
Fluticasone Propiyonat	Corticosteroids	7
Fosaprepitant Dimeglumin	Antiemetics	7
Heparin Sodium	Antithrombotic	7
Hyoscine-N-Butylbromide	Antispazmodic	8
lohexol	Diagnostic Agents	8
lopromide	Diagnostic Agents	8
Ibuprofen	Analgesic-Antipyretic	9
Ibuprofen	PDA Treatment	9
Icatibant Acetate	Hereditary Angioedema Treatment	9
Ipratropium Bromide and Salbutamol	Bronchodilator	9
Levetiracetam	Epilepsy Treatment	10
Levofloxacin Hemihydrate	Antibacterial	10
Levosimendan	Cardiac Stimulant	10
Linezolid	Antibacterial	10
L-Ornithine L-Aspartate	Hepatic Encephalopathy	10
Metamizole Sodium	Analgesic-Antipyretic	11
Methylprednisolone Sodium Succinate	Corticosteroid	11
Metronidazole	Antibacterial	11
Micafungin	Antifungal	12
Moxifloxacin Hydrochloride	Antibacterial	12
Multivitamin	Vitamin Deficiency Treatment	12
Neostigmine Methyl Sulfate	Acetyl Cholinesterase Inhibitor	12
Omeprazol Sodium	Proton Pump Inhibitor	13
Ondansetron Hydrochloride Dihydrate	Antiemetics	13
Palonosetron HCI	Antiemetics	13
Pantoprazole Sodium Sesquihydrate	Proton Pump Inhibitor	13
Paracetamol	Analgesic-Antipyretic	13
Paricalcitol	Anti-Parathyroid	14
Pheniramine Maleate	Antihistaminic	14
Piracetam	Psychostimulant and Nootropic	14
Posaconazole	Antifungal	15
Prilocaine HCI	Local Anesthetic	15
Propofol	General Anesthesia	15

## SMALL VOLUME PARENTERALS

ACTIVE INGREDIENT	THERAPEUTIC FIELD	PAGE
Rocuronium Bromide	Skeletal Muscle Relaxant	16
Salbutamol Sulfate		17
Sevoflurane	General Anesthesia	17
Sugammadex	Reversal of Neuromuscular Blockage	17
Teicoplanin	Antibacterial	18
Tenoxicam	Analgesic, Anti-Inflammatory	18
Theophyphilline Anhydrus	Bronchodilator	18
Tigecycline	Antibacterial	19
Tirofiban HCI	Antithrombotic	19
Vancomycin Hydrochloride	Antibacterial	19
Vecuronium Bromide	Skeletal Muscle Relaxant	20
Voriconazole	Antifungal	20
Zoledronic Acid Monohydrate	Bone Loss Treatment Due to Chemotherapy	20

## **NUTRITION SOLUTIONS**

3-Chamber Bag Nutritional Solution	
Lipid Emulsion	22
Amino Acid Solution	23

### LARGE VOLUME PARENTERALS

Basic (Standard) I.V. Solutions	26
Multiple Electrolyte Solutions	31
Plasma Volume Complementary Solutions	36

## **MEDICAL DEVICES**

Irrigation Solution	39
Catheter Lock Solution	41
Infusion Set	42

### **VETERINARY PRODUCT**

## Small volume Parenterals

A POLIFARMA

MUFINES 100 MG LYC SOLUTION FOR I.V. IN	OPHILIZED POWDER FOR NFUSION	2- Cold Chain Product	
DOSE	100 mg, 1 Lyophilized Vial		Do multives Power for Solution for V. Wristion
PACKAGING	VIAL		Aniduaturgin
ACTIVE INGREDIENT	Anidulafungin		Sorte Strategy Strate
THERAPEUTIC FIELD	ANTIFUNGAL		t cyrestiter Yar
CLINICAL USAGE	INFECTIOUS DISEASES		

#### ANTOKSİ-C 500 MG/5 ML SOLUTION FOR I.V. INJECTION

VOLUME	5 ml x 5 Ampoules	Antoksi-C 500 mg/ 5ml
PACKAGING	AMPOULE	Assertice Actid (Vitamin C) Series Aministered intraversory
ACTIVE INGREDIENT	Ascorbic Acid (Vitamin C)	STALES Amounts
THERAPEUTIC FIELD	VITAMIN C DEFICIENCY	Smix S Ampoules
CLINICAL USAGE	ALL CLINICS	

#### CYSTEPOL 300 MG/3 ML SOLUTION FOR INJECTION

VOLUME	3 ml x 10 Ampoules	Cystepol 300 mg/3 mL Solution For Injection
PACKAGING	AMPOULE	Antervening Dirition DIV. A demonstrativy instances are strategically large
ACTIVE INGREDIENT	Acetylcysteine	July 10 margan
THERAPEUTIC FIELD	MUCOLITIC, ASETAMINOFEN ANTIDOTE	
CLINICAL USAGE	ALL CLINICS	

ASIMPLEX 250 MG LY	OPHILIZED POWDER FOR SOLUTION FOR INFUSION	
DOSE	250 mg, 1 Lyophilized Vial / 5 Lyophilized Vials	Asimplex 250 mg System for System for Instance
PACKAGING	VIAL	Acyclovir Asimplex
ACTIVE INGREDIENT	Acyclovir	Sterile - LV. Infusion
THERAPEUTIC FIELD	ANTIVIRAL	1 Lyophilized Viai
CLINICAL USAGE	INFECTIOUS DISEASES	

VOLUME	20 ml x 1 Vials		
PACKAGING	VIAL	Buvicaine 0.5 % Isator fur firefisia	/
ACTIVE INGREDIENT	Bupivacaine HCI	Beneficial Security of Information	
THERAPEUTIC FIELD	LOCAL ANESTHETIC	A series 1 voie	
CLINICAL USAGE	ANESTHESIA		

TEORY 1 MCG/ML I.V.	INJECTION SOLUTION		
VOLUME	1 ml x 25 ampoules	Teory 1 mcg/ml V: lejetics Solution	
PACKAGING	AMPOULE	Barris-1,V. Hjecton Galerny Galerny	
ACTIVE INGREDIENT	Calcitriol	Int z 25 Anyouis	
THERAPEUTIC FIELD	VITAMIN D ANALOGUE		
CLINICAL USAGE	HEMODIALYSIS		

#### **TEORY 2 MCG/ML I.V. INJECTION SOLUTION**

VOLUME	1 ml x 25 ampoules	Teory 2 mcg/ml
PACKAGING	AMPOULE	IV. Injector Station Write the provide stat
ACTIVE INGREDIENT	Calcitriol	A refer dame with all Allows Service and an annual allows Service and annual allows Service and allows
THERAPEUTIC FIELD	VITAMIN D ANALOGUE	Ini 123 deguare
CLINICAL USAGE	HEMODIALYSIS	

CASPOPOL 50 MG LYOPHILIZED POWDER FOR	
SOLUTION FOR I.V. INFUSION	

CASPOPOL 50 MG LY SOLUTION FOR I.V. IN	OPHILIZED POWDER FOR	2*• Cold Chain Product			
DOSE	50 mg, 1 Lyophilized Vial		Caspopol 50 mg Lycophilied Powder for		
PACKAGING	VIAL		Solution for LV. Infusion		
ACTIVE INGREDIENT	Caspofungin Acetate		Sterile	Caspopol 50 mg Lynghilised Powder for Solution for LV: Infusion Caspotungin	
THERAPEUTIC FIELD	ANTIFUNGAL		50 1 Lyophilised Vial		
CLINICAL USAGE	INFECTIOUS DISEASES				/

## CASPOPOL 70 MG LYOPHILIZED POWDER FOR SOLUTION FOR I.V. INFUSION

CASPOPOL 70 MG LY SOLUTION FOR I.V. IN	OPHILIZED POWDER FOR FUSION	200 Cold Chain Product			
DOSE	70 mg, 1 Lyophilized Vial		Caspopol 70 mg		
PACKAGING	VIAL		Solution for L.V. Infusion Caspolurgin		
ACTIVE INGREDIENT	Caspofungin Acetate		Sterile	Caspopol 70 m Lynahilised Powder M Solution for LV, Infusion Caspofungin Mit - Ambusteres Mozamini	
THERAPEUTIC FIELD	ANTIFUNGAL		1 Lyophilised Vial		
CLINICAL USAGE	INFECTIOUS DISEASES				*

CIPRODEKS 2 MG/ML	SOLUTION FOR I.V. INFUSION	
VOLUME	100 ml, 200 ml	CLIFEES A.G. EXPENSION CONTRACTOR OF THE ACCOUNT
PACKAGING	PP BAG	The second secon
ACTIVE INGREDIENT	Ciprofloxacin Lactate	Hard Hard Hard Hard Hard Hard Hard Hard
THERAPEUTIC FIELD	ANTIBACTERIAL	
CLINICAL USAGE	INFECTIOUS DISEASES	

CIPROPOL 2 MG/ML	SOLUTION FOR I.V. INFUSION	
VOLUME	100 ml, 200 ml	POLIFIESE* 200 FM THE THE THE THE THE THE THE THE THE THE
PACKAGING	PP BAG	The second secon
ACTIVE INGREDIENT	Ciprofloxacin Lactate	Normalization of the second se
THERAPEUTIC FIELD	ANTIBACTERIAL	
CLINICAL USAGE	INFECTIOUS DISEASES	

#### VONECIP 400 MG/200 ML SOLUTION FOR I.V. INFUSION

VOLUME	200 ml	
PACKAGING	VIAL	
ACTIVE INGREDIENT	Ciprofloxacin Lactate	
THERAPEUTIC FIELD	ANTIBACTERIAL	42 200 MI 1 VAI
CLINICAL USAGE	INFECTIOUS DISEASES	

#### VONECIP 200 MG/100 ML SOLUTION FOR I.V. INFUSION

		- A ANY TRADE BOOM
VOLUME	100 ml	Vonecip
PACKAGING	VIAL	200 mg/100 ml Soutientor LY infusion
ACTIVE INGREDIENT	Ciprofloxacin Lactate	Curedusan Exterior C. social
THERAPEUTIC FIELD	ANTIBACTERIAL	BO MU X 1 VIII
CLINICAL USAGE	INFECTIOUS DISEASES	

## KOLİSTİPOL 4.500.000 IU POWDER AND SOLVENT FOR SOLUTION FOR I.V INJECTION AND INHALATION

DOSE	4.500.000 IU, 1 Lyophilized Vial + 1 Ampoule	Kolistipol Accessible for Accessible
PACKAGING	VIAL	
ACTIVE INGREDIENT	Colistimethate Sodium	Mark Address of Williams And Address of Walks and A
THERAPEUTIC FIELD	ANTIBACTERIAL	i Solice Legend
CLINICAL USAGE	INFECTIOUS DISEASES	

## DEKSTOMID 200 MCG/2 ML CONCENTRATED SOLUTION FOR I.V. INFUSION VOLUME 2 ml x 5 Vials PACKAGING VIAL ACTIVE INGREDIENT Dexmedetomidine HCI THERAPEUTIC FIELD SEDATIVE & HYPNOTIC CLINICAL USAGE ANESTHESIA, INTENSIVE CARE

#### MEKARD 250 MG/20 ML CONCENTRATED SOLUTION FOR I.V. INFUSION

VOLUME	20 ml x 10 Ampoules	MEKARD 250 mg/20 m
PACKAGING	AMPOULE	Concentrated Solution for LV. Infrash
ACTIVE INGREDIENT	Dobutamine Hydrochloride	
THERAPEUTIC FIELD	CARDIAC STIMULANT	20 mix 10 Amprovi
CLINICAL USAGE	ANESTHESIA, INTENSIVE CARE, CARDIOLOGY	

#### VENAPERTA 2000 ANTI-XA IU/0.2 ML PRE-FILLED SYRINGE

VOLUME	0.2 ml x 2 syringes	
PACKAGING	PFS	VENAPERTA 2000 AntiXA IV/Or mL Solution For Injection In Pre-filled Syringe
ACTIVE INGREDIENT	Enoxaparin Sodium	Exception to Refer References to Advancements or UK-and Advancements of Advancements for the Advancements of
THERAPEUTIC FIELD	LOW MOLECULAR WEIGHT HEPARIN	
CLINICAL USAGE	ALL CLINICS	

#### VENAPERTA 4000 ANTI-XA IU/0.4 ML PRE-FILLED SYRINGE

VOLUME	0.4 ml x 10 syringes	VENAPERTA 4000 Anti-TA IU/BA HE
		Exhibition For Injection in Profiled Syntrage
PACKAGING	PFS	men and the second seco
ACTIVE INGREDIENT	Enoxaparin Sodium	
THERAPEUTIC FIELD	LOW MOLECULAR WEIGHT HEPARIN	
CLINICAL USAGE	ALL CLINICS	

#### VENAPERTA 6000 ANTI-XA IU/0.6 ML PRE-FILLED SYRINGE

VOLUME	0.6 ml x 2 syringes	VENAPERTA 6000 Anti-XA IU/000
PACKAGING	PFS	VENAPERTA 6000 ANTIVATO Solidar Formation In Preference Synthese International Control of Control o
ACTIVE INGREDIENT	Enoxaparin Sodium	
THERAPEUTIC FIELD	LOW MOLECULAR WEIGHT HEPARIN	
CLINICAL USAGE	ALL CLINICS	

VENAPERTA 10000	ANTI-XA IU/1 ML PRE-FILLED SYRINGE	
VOLUME	1 ml x 2 syringes	
PACKAGING	PFS	VENAPERTA votoo Anti-XA IV/1mt Solution For Injection in Pre-filed Symmet
ACTIVE INGREDIENT	Enoxaparin Sodium	
THERAPEUTIC FIELD	LOW MOLECULAR WEIGHT HEPARIN	
CLINICAL USAGE	ALL CLINICS	

#### ESMOBLOC 10 MG/ML SOLUTION FOR I.V. INFUSION

VOLUME	250 ml	POLIFIERS 250 mi Communications BESIMOBALISTIC DA LA INVISION
PACKAGING	PP BAG	FUEL APPROX HILD AND A DECEMBER AND
ACTIVE INGREDIENT	Esmolol Hydrochloride	- A set of the set of
THERAPEUTIC FIELD	SUPRAVENTRICULAR TACHYCARDIA AND HYPERTENSION TREATMENT	
CLINICAL USAGE	ANESTHESIA, INTENSIVE CARE	

#### ESMOBLOC 20 MG/ML SOLUTION FOR I.V. INFUSION

VOLUME	100 ml	
PACKAGING	PP BAG	How it and the second sec
ACTIVE INGREDIENT	Esmolol Hydrochloride	<ul> <li>The second secon</li></ul>
THERAPEUTIC FIELD	SUPRAVENTRICULAR TACHYCARDIA AND HYPERTENSION TREATMENT	
CLINICAL USAGE	ANESTHESIA, INTENSIVE CARE	

#### ESSIUM 40MG POWDER FOR SOLUTION FOR I.V. INJECTION/INFUSION

DOSE	40 mg, 1 Lyophilized Vial	Essium to mp power for Statition for W. Intertanihilation	
PACKAGING	VIAL	For IV. Injection mission Esomorrazele	
ACTIVE INGREDIENT	Esomeprazole sodium	Strefe V. Precedar/Masian	
THERAPEUTIC FIELD	PROTON PUMP INHIBITOR	Ly operation vision	
CLINICAL USAGE	ALL CLINICS		

#### FENTANYL-PF 100 MCG/2 ML SOLUTION I.V./I.M. INJECTION

VOLUME	2 ml x 10 Ampoules	
PACKAGING	AMPOULE	Solution For LV/LM. Injection
ACTIVE INGREDIENT	Fentanyl Citrate	And a Standard or interested      A
THERAPEUTIC FIELD	OPIOID ANALGESICS	
CLINICAL USAGE	ANESTHESIA, INTENSIVE CARE	

FENTANYL-PF 500 M	CG/10 ML SOLUTION I.V./I.M. INJECTION	
VOLUME	10 ml x 1 Ampoules	Fentanyl-PF Soution for V.//M. Injection Fentanyl Citrate
PACKAGING	AMPOULE	Sterile Administed Internusculfy or Intravenously
ACTIVE INGREDIENT	Fentanyl Citrate	intanyl-P 10 regrota
THERAPEUTIC FIELD	OPIOID ANALGESICS	entrance and a second sec
CLINICAL USAGE	ANESTHESIA, INTENSIVE CARE	

#### FLUKODEKS 2 MG/ML SOLUTION FOR I.V. INFUSION

VOLUME	100 ml, 200 ml	POLICIE Fundamentaria Tanàn Tanàna Tanàn Tanàna Tanàn Tanàna Tanà
PACKAGING	PP BAG	III 1-1-1-1     INFORMET     INFORMATING
ACTIVE INGREDIENT	Fluconazole	a success a constant.
THERAPEUTIC FIELD	ANTIFUNGAL	
CLINICAL USAGE	INFECTIOUS DISEASES	

#### FLUKOL 100 MG/50 ML SOLUTION FOR I.V. INFUSION

VOLUME	50 ml	
PACKAGING	VIAL	Flukol 100 mg/50 ml Sosteri dr L. Andre
ACTIVE INGREDIENT	Fluconazole	Visition Visition 100 million
THERAPEUTIC FIELD	ANTIFUNGAL	S0 ml x 1 vial
CLINICAL USAGE	INFECTIOUS DISEASES	

#### FLUKOPOL 2 MG/ML SOLUTION FOR I.V. INFUSION

VOLUME	50 ml, 100 ml, 200 ml	NUTLUE The state of the state
PACKAGING	PP BAG	The second secon
ACTIVE INGREDIENT	Fluconazole	in the matrix and the
THERAPEUTIC FIELD	ANTIFUNGAL	
CLINICAL USAGE	INFECTIOUS DISEASES	

~

#### ANESED-R 0.5 MG/5 ML SOLUTION FOR I.V. INJECTION

VOLUME	5 ml x 5 ampoules	Anesed-R 0,5 mg/5 ml	
PACKAGING	AMPOULE	Furnazenii Storile Fort V. Use	
ACTIVE INGREDIENT	Flumazenil	Lassed- SamySe Madate Madate	
THERAPEUTIC FIELD	BENZODIAZEPINE ANTIDOTE	Smix S Argode	
CLINICAL USAGE	ANESTHESIA, INTENSIVE CARE		

ANESED-R 1 MG/10 M	IL SOLUTION FOR I.V. INJECTION		
VOLUME	10 ml x 5 ampoules	Anesed-R 1 mg/10 ml Solution for LV. Injection	
PACKAGING	AMPOULE	Plamazenii Sterile For I.V. Use	
ACTIVE INGREDIENT	Flumazenil		Anesed-R Ime/ION Interest V. Interest States For Sty Day
THERAPEUTIC FIELD	BENZODIAZEPINE ANTIDOTE	10 mi x 5 Ampoule	
CLINICAL USAGE	ANESTHESIA, INTENSIVE CARE		

#### FLUSIBLE 500 MG/5 ML I.V. SOLUTION FOR I.V. INJECTION

VOLUME	5 ml x 1 Vial	
PACKAGING	VIAL	Sourd 5 m Setution for I.V. Spiection
ACTIVE INGREDIENT	Fluorescein Sodium	Sterile 1.V. Injection
THERAPEUTIC FIELD	IMAGING AGENT	s mi x i Viai
CLINICAL USAGE	FLUORESCENCE ANGIOGRAPHY	

#### NASATICONE 0,1% NASAL DROP, SUSPENSION

VOLUME	0,4 ml x 30 Vial	NASATICONE 01%
PACKAGING	BFS	
ACTIVE INGREDIENT	Fluticasone Propiyonat	
THERAPEUTIC FIELD	CORTICOSTEROIDS	
CLINICAL USAGE	CHEST DISEASES, ALERGY	

#### BRETICASONE 2 MG/2 ML NEBULISER SUSPENSION

VOLUME	2 ml x 10 Vial	Breticasone
PACKAGING	BFS	
ACTIVE INGREDIENT	Fluticasone Propiyonat	n Polifanna
THERAPEUTIC FIELD	CORTICOSTEROIDS	
CLINICAL USAGE	CHEST DISEASES, ALERGY	

## FOSEMAZON 150 MG POWDER FOR CONCENTRATE SOLUTION FOR I.V INFUSION

FOSEMAZON 150 MG POWDER FOR CONCENTRATE SOLUTION FOR I.V INFUSION		2° Julio Cold Chain Product			
VOLUME	150 mg, 1 Lyophilized Vial		Fosemazon 150 mg Powder for Concentrate Solution for I.V. Infusion	-	
PACKAGING	VIAL		Fosaprepitant		
ACTIVE INGREDIENT	Fosaprepitant Dimeglumine		Sterile L.V. Infusion	Fosemazon 150 mg Powder for Concentrate Solution for LV. Infusion Foseprepitant Sterile-I.V. Infusion	
THERAPEUTIC FIELD	ANTIEMETICS		1 Lyopilized Viat	The second secon	
CLINICAL USAGE	ONCOLOGY				

POLIPARIN 25000 IN INFUSION	J/5 ML SOLUTION FOR I.V./S.C. INJECTION AND	
VOLUME	5 ml x 1 Vial	Poliparin
PACKAGING	VIAL	25000 IU/5 ml Solition for W/SC Injection and Maxim
ACTIVE INGREDIENT	Heparin Sodium	Antecopy of the second
THERAPEUTIC FIELD	ANTITHROMBOTIC	Constant visit
CLINICAL USAGE	CARDIOLOGY, HEMODIALYSIS	

#### HİYOSPAZM 20 MG/ML SOLUTION FOR IM/SC/IV INJECTION

VOLUME	1 ml x 6 Ampoules	Hiyospazm 20 mg/mL Solution for IM/IV/SC Injection
PACKAGING	AMPOULE	Hypercine W-burythremide
ACTIVE INGREDIENT	Hyoscine-N-Butylbromide	Admitted by promotion.
THERAPEUTIC FIELD	ANTISPASMODIC	1 mi x 6 viats Territory
CLINICAL USAGE	ALL CLINICS	

#### OMNIPOL 300 MG I/ML SOLUTION FOR I.A., I.V. INTRATHECAL INJECTION

VOLUME	50 ml, 100 ml	
PACKAGING	VIAL	Omnipol 300 mg l/mi L. Le transformente
ACTIVE INGREDIENT	lohexol	Larent Screin, autorian Die maj / m
THERAPEUTIC FIELD	DIAGNOSTIC AGENTS	
CLINICAL USAGE	RADIOLOGY	

OMNİPOL 350 MG I/M	1L SOLUTION FOR I.A., I.V. INJECTION	
VOLUME	50 ml, 100 ml, 200 ml	Omnipol
PACKAGING	VIAL	333 mg / m L. us ingertim
ACTIVE INGREDIENT	lohexol	
THERAPEUTIC FIELD	DIAGNOSTIC AGENTS	I con mi a t viu
CLINICAL USAGE	RADIOLOGY	

IOPOLIMID 300 MG I	ML SOLUTION FOR INJECTION	
VOLUME	50 ml, 100 ml	
PACKAGING	VIAL	Solution for Injection
ACTIVE INGREDIENT	lopromide	
THERAPEUTIC FIELD	DIAGNOSTIC AGENTS	
CLINICAL USAGE	RADIOLOGY	

IOPOLIMID 370 MG I	ML SOLUTION FOR INJECTION	
VOLUME	50 ml, 100 ml, 200 ml	iopolimid
PACKAGING	VIAL	Sandan for Injection
ACTIVE INGREDIENT	lopromide	A A A A A A A A A A A A A A A A A A A
THERAPEUTIC FIELD	DIAGNOSTIC AGENTS	100 ml 1 1 viti
CLINICAL USAGE	RADIOLOGY	

#### **IBUPROFEN-PF 800 MG/8 ML SOLUTION FOR I.V. INFUSION**

VOLUME	8 ml x 1 Vials / 10 Vials	
PACKAGING	VIAL	ibuprofen-PF 800 me / 8 ml Solution for LV. Intusion
ACTIVE INGREDIENT	Ibuprofen	Stelle for I.V. Infusion Only
THERAPEUTIC FIELD	ANALGESIC-ANTIPYRETIC	
CLINICAL USAGE	ALL CLINICS	

#### **İBUPROFEN-PF 400 MG/4 ML SOLUTION FOR I.V. INFUSION**

VOLUME	4 ml x 1 Vials / 10 Vials	[buprofen-PF
PACKAGING	VIAL	Solution For LV. Influsion
ACTIVE INGREDIENT	Ibuprofen	Sterile For L.V. Infusion Only 60
THERAPEUTIC FIELD	ANALGESIC-ANTIPYRETIC	4 mi x 1 Viai
CLINICAL USAGE	ALL CLINICS	

#### PATENTOFEN 10 MG/2 ML SOLUTION FOR I.V. INFUSION

VOLUME	2 ml x 4 Ampoules	Patentofen 10 mg/2 mL Solution For I.V. Infusion
PACKAGING	AMPOULE	Ibuprefen
ACTIVE INGREDIENT	Ibuprofen	Bagreles Strikes V. Infusion
THERAPEUTIC FIELD	PDA TREATMENT CARDIOVASCULAR SYSTEM	2 mi x 4 angoules Angoli Canada Canad
CLINICAL USAGE	NEONATAL INTENSIVE CARE	

#### BRADİKANT 30 MG/3 ML SOLUTION FOR S.C. INJECTION FILLED SYRINGE 1 VOLUME 3 ml Injector + Hypodermic Needle Bradikant 30 mg/3 ml Ing(): #//W/W//W PACKAGING PFS ē. ACTIVE INGREDIENT **Icatibant Acetate** THERAPEUTIC FIELD HEREDITARY ANGIOEDEMA TREATMENT CLINICAL USAGE ALLERGY-IMMUNOLOGY

DUBLEVENT 0.5 MG+	2.5 MG/2.5 ML NEBULIZATION SOLUTION	
VOLUME	2.5 ml x 20 Ampoules	B Dublevent 0,5 mg+2,5 mg/2,5 mL
PACKAGING	AMPOULE	Nebulization over-
ACTIVE INGREDIENT	Ipratropium Bromide and Salbutamol	2 c mL x 20 Ampoules
THERAPEUTIC FIELD	BRONCHODILATOR	
CLINICAL USAGE	RESPIRATORY TRACT DISEASES	

#### LEVETAM 500 MG/5 ML CONCENTRATED SOLUTION FOR INFUSION

VOLUME	5 ml x 10 Vial	7
PACKAGING	VIAL	Levetam 500 mg/5 ml Concentrated Solidar for Influence Narkit «Kiman
ACTIVE INGREDIENT	Levetiracetam	Entrifaction 5 ml x 10 visio
THERAPEUTIC FIELD	EPILEPSY TREATMENT	
CLINICAL USAGE	NEUROLOGY, NEUROSURGERY	

#### LEVOXIPOLIN 500 MG/100 ML SOLUTION FOR I.V. INFUSION

VOLUME	100 ml	COLFREGS 100 M CAROLINU LEVOXIPOLIN 500 mg 100 m SOLUTION OF IX MUSICIN STAR L'A VARIAN
PACKAGING	PP BAG	The second and the se
ACTIVE INGREDIENT	Levofloxacin Hemihydrate	The second
THERAPEUTIC FIELD	ANTIBACTERIAL	
CLINICAL USAGE	INFECTIOUS DISEASES	

SİMENDAN 12,5 MG/ FOR I.V. INFUSION	5 ML CONCENTRATED SOLUTION	2*• Cold Chain Product		
VOLUME	5 ml x 1 Vial			
PACKAGING	VIAL		Simendan 12,5 mg/5 ml Concentrated Solution for LV- Infusion	
ACTIVE INGREDIENT	Levosimendan		Evststmenden For LV. Administration. Stoletie abloed apprecisitely betre uik. See patient	Simendan 12,5 mg/5 m Goncentrated Saulion for LV, Infusion Levosimendan
THERAPEUTIC FIELD	CARDIAC STIMULANT		5 mi x 1 viai	
CLINICAL USAGE	CARDIOLOGY			

#### POLINOKSID 2 MG/ML I.V. SOLUTION FOR INFUSION

VOLUME	300 ml	TO LTPLES 300 mil Construction of the second
PACKAGING	PP BAG	And improve that the second se
ACTIVE INGREDIENT	Linezolid	
THERAPEUTIC FIELD	ANTIBACTERIAL	
CLINICAL USAGE	INFECTIOUS DISEASES	

HEPALORNITIN 5 G/1	0 ML CONCENTRATE SOLUTION FOR I.V. INFUSION			
VOLUME	10 ml x 10 Ampoules	Hepalornitin 5 g/10 ml		
PACKAGING	AMPOULE	L-Omitin L- Aspartat Sovie VV. Hitzyon		
ACTIVE INGREDIENT	L-Ornithine L-Aspartate		Iconformiti 100 mil Concern 100 mil Concern 100 mil Concern 100 mil Concern	
THERAPEUTIC FIELD	HEPATIC ENCEPHALOPATHY	Do not use without distant.	Ĵ	
CLINICAL USAGE	GASTROENTEROLOGY, INTERNAL MEDICINE			

#### NOVO-PLAN 1G/2ML SOLUTION FOR I.M./I.V. INJECTION

VOLUME	2 ml x 10 Ampoules / 100 Ampoules	
PACKAGING	AMPOULE	Novo-Plan 1 g/2 ml Solution for LM/LV. Injection
ACTIVE INGREDIENT	Metamizole Sodium	Hermite Andrea Serrick (12) venture
THERAPEUTIC FIELD	ANALGESIC-ANTIPYRETIC	2 mi x 10 Ampoule
CLINICAL USAGE	ALL CLINICS	

CORTIPOL 20 MG PO I.M./I.V. INJECTION	WDER AND SOLVENT FOR SOLUTION FOR	
DOSE	20 mg, 1 Lyophilized Ampoule + 1 Solvent Ampoule	Cortipol 20 mp Proor and Saland For Smallin Fer MUNAL Herition
PACKAGING	AMPOULE	Serie Bartin Bartin
ACTIVE INGREDIENT	Methylprednisolone Sodium Succinate	An and a second se
THERAPEUTIC FIELD	CORTICOSTEROID	
CLINICAL USAGE	ALL CLINICS	

CORTIPOL 40 MG PO I.M./I.V. INJECTION	OWDER AND SOLVENT FOR SOLUTION FOR	
DOSE	40 mg, 1 Lyophilized Ampoule + 1 Solvent Ampoule	Ar my very distance
PACKAGING	AMPOULE	Methylareditalation Savia Methylareditalation
ACTIVE INGREDIENT	Methylprednisolone Sodium Succinate	Tundension
THERAPEUTIC FIELD	CORTICOSTEROID	
CLINICAL USAGE	ALL CLINICS	

CORTIPOL 250 MG P I.M./I.V. INJECTION	OWDER AND SOLVENT FOR SOLUTION FOR				
DOSE	250 mg, 1 Lyophilized Ampoule + 1 Solvent Ampoule	Cortipol 250 mg UALAV. Pender and Safered in			
PACKAGING	AMPOULE	Subject to Larger Version			
ACTIVE INGREDIENT	Methylprednisolone Sodium Succinate	1 geptinger Ammen	Cortipol 190 mg LMAX Weler and Solid To Saturtion for MAX V, hypertin Whyteredenionin Statistic WAX V, hypertin Statistic WAX V, hypertin Statistic WAX V, hypertin Statistic WAX V, hypertin Statistic WAX V, hypertin Statistic	a mi eter for Serile	/
THERAPEUTIC FIELD	CORTICOSTEROID			OLIFAN	
CLINICAL USAGE	ALL CLINICS				

VOLUME	100 ml	
PACKAGING	PP BAG	EXCITING FOR IN PERFORM ETHEL: - VALUE MATHEMAN MATHA
ACTIVE INGREDIENT	Metronidazole	The second
THERAPEUTIC FIELD	ANTIBACTERIAL	
CLINICAL USAGE	INFECTIOUS DISEASES	

#### MIKAFUNGUS 50 MG POWDER FOR SOLUTION FOR I.V. INFUSION

DOSE	50 mg x 1 vial	Mikafungus Somg Power for Soution
PACKAGING	VIAL	for LV. Influeion Micafungin
ACTIVE INGREDIENT	Micafungin	Sterile V., Indusion
THERAPEUTIC FIELD	ANTIFUNGAL	TLynabilized Viai
CLINICAL USAGE	INFECTIOUS DISEASES	

#### MİKAFUNGUS 100 MG POWDER FOR SOLUTION FOR I.V. INFUSION

		and a state of the second	
DOSE	100 mg x 1 vial	Mikafungus 100 mg Powder for Solution For UV, Infusion	
PACKAGING	VIAL	Micafungin	
ACTIVE INGREDIENT	Micafungin	Sterile LV. Infusion	Wikafungus 100 m Power for Solution for U.V. Instain Micafungin Service U.V. Instain
THERAPEUTIC FIELD	ANTIFUNGAL	1 Lyophilzed Visi	
CLINICAL USAGE	INFECTIOUS DISEASES		

#### MOKSILOX 400 MG/250 ML SOLUTION FOR I.V. INFUSION

VOLUME	250 ml	FOLSTACKS <sup>6</sup> There are a reason with the second se	
PACKAGING	PP BAG	Network water wate	
ACTIVE INGREDIENT	Moxifloxacin Hydrochloride	The second secon	
THERAPEUTIC FIELD	ANTIBACTERIAL		(
CLINICAL USAGE	INFECTIOUS DISEASES		

#### TODAVİT POWDER FOR SOLUTION FOR I.M./I.V INJECTION/INFUSION

VOLUME	4 Lyophilized Vials	
PACKAGING	VIAL	Todavít Pretr tr Sultan tr
ACTIVE INGREDIENT	MULTIVITAMIN	
THERAPEUTIC FIELD	VITAMIN DEFICIENCY TREATMENT	Aurenterne PF
CLINICAL USAGE	ALL CLINICS	

#### PLANTIGMIN 0.5 MG/ML SOLUTION FOR INJECTION

VOLUME	1 ml x 6 Ampoules	And the second se
PACKAGING	AMPOULE	Plantigmin 0.5 mg/ml
ACTIVE INGREDIENT	Neostigmine Methyl Sulfate	Shorts Sh
THERAPEUTIC FIELD	ACETYL CHOLINESTERASE INHIBITOR	1 ml x 6 ampoule
CLINICAL USAGE	ALL CLINICS	

OMEPREFUL 40 MG FOR I.V. INJECTION	POWDER AND SOLVENT FOR SOLUTION	
VOLUME	40 mg, 1 Lyophilized Vial + 1 Solvent Ampoule	Omepreful 45 rap Perete and Solvert to Solution for 1X. Pyeetion
PACKAGING	VIAL	
ACTIVE INGREDIENT	Omeprazole Sodium	Extra La Constantina de la Con
THERAPEUTIC FIELD	PROTON PUMP INHIBITOR	Legendar for the second
CLINICAL USAGE	ALL CLINICS	

#### NAUZEX 8 MG/4 ML SOLUTION FOR I.M./I.V. INJECTION/INFUSION

		and a start of the distance	
VOLUME	4 ml x 1 Ampoules	B mg/4 ml Soldish or M/IV Intection/Intelling	
PACKAGING	AMPOULE	C-description Hereinshifter Dialydrafter Stellan Heldan	
ACTIVE INGREDIENT	Ondansetron Hydrochloride Dihydrate	Nauzen Anderen	
THERAPEUTIC FIELD	ANTIEMETICS		
CLINICAL USAGE	ONCOLOGY, ANESTHESIA		

#### ZÍAXE 250 MCG/5 ML SOLUTION FOR I.V. INJECTION

		and the second second
VOLUME	5 ml x 1 Vial	Ziaxe
PACKAGING	VIAL	250 mcg/5 ml Solution for IV. Injection
ACTIVE INGREDIENT	Palonosetron HCI	Sterile - LV. Injection
THERAPEUTIC FIELD	ANTIEMETICS	Smittal 🏔
CLINICAL USAGE	ONCOLOGY	

#### ZYGOSIS 40 MG LYOPHILISED POWDER FOR SOLUTION FOR I.V. INJECTION

			< l>
DOSE	40 mg, 1 Lyophilized Vial	Zygosis	
PACKAGING	VIAL	Add mit Johannahan Power front Kinden Part V. Nijection Partorazale	
ACTIVE INGREDIENT	Pantoprazole Sodium Sesquihydrate	Serier LV. Netcon Serier La Source Series Sources	/
THERAPEUTIC FIELD	PROTON PUMP INHIBITOR	1 Lynshilized Var No eel	
CLINICAL USAGE	ALL CLINICS		

PARACEROL 10 MG/M	IL VIAL CONTAINING SOLUTION FOR I.V. INFUSION	
VOLUME	100 ml x 12 Vials	
PACKAGING	VIAL	
ACTIVE INGREDIENT	Paracetamol	Paracerol 10 mg/ml Via Containing Solution for LV. Introdu
THERAPEUTIC FIELD	ANALGESIC-ANTIPYRETIC	Sterie - LV. Jobules 100 ml Vial Pull here to hang visi
CLINICAL USAGE	ALL CLINICS	

#### POLAMINOFEN 10 MG/ML IV. SOLUTION FOR INFUSION

VOLUME	100 ml x 12 Bags / 1 Bag	
PACKAGING	PP BAG	<ul> <li>A strandball constraint of the s</li></ul>
ACTIVE INGREDIENT	Paracetamol	
THERAPEUTIC FIELD	ANALGESIC-ANTIPYRETIC	
CLINICAL USAGE	ALL CLINICS	

#### RECHROSITOL 10 MCG/2ML I.V. INJECTION SOLUTION

VOLUME	2 ml x 5 ampoules	Rechrositol 10 mcg/2 ml
PACKAGING	AMPOULE	Paricacita Sterie N. Intection
ACTIVE INGREDIENT	Paricalcitol	
THERAPEUTIC FIELD	ANTI-PARATHYROID	2 ml 3 amportes
CLINICAL USAGE	HEMODIALYSIS	

#### **RECHROSITOL 5 MCG/ML I.V. INJECTION SOLUTION**

VOLUME	1 ml x 5 ampoules	Rechrositol 5 meg/ml
PACKAGING	AMPOULE	Parkakitai Storia W. Ingeston
ACTIVE INGREDIENT	Paricalcitol	
THERAPEUTIC FIELD	ANTI-PARATHYROID	1 ml 5 ampoules
CLINICAL USAGE	HEMODIALYSIS	

#### FENIRAMIN-PF 45.5 MG/2 ML SOLUTION FOR I.M./I.V. INJECTION

VOLUME	2 ml x 5 Ampoules	Feniramin-PF 45.5 mg/2 ml Solution for LM./LV, Injection
PACKAGING	AMPOULE	Pheninamine maleate Service I.M./I.V. Injection
ACTIVE INGREDIENT	Pheniramine Maleat	
THERAPEUTIC FIELD	ANTIHISTAMINIC	
CLINICAL USAGE	ALL CLINICS	

L IV SOLUTION FOR INFUSION	
5 ml x 12 Ampoules	Neurosetam 1 g/5 ml
AMPOULE	Pracetan Strine LV. Infusion
Piracetam	
PSYCHOSTIMULANT AND NOOTROPIC	S mi x 12 Ampoules
NEUROLOGY	
	5 ml x 12 Ampoules         AMPOULE         Piracetam         PSYCHOSTIMULANT AND NOOTROPIC

# POSECTIO 300 MG CONCENTRATED FOR PREPARING I.V. SOLUTION FOR INFUSION VOLUME 16.7 ml x 1 vial PACKAGING VIAL ACTIVE INGREDIENT Posaconazole THERAPEUTIC FIELD ANTIFUNGAL CLINICAL USAGE INFECTIOUS DISEASES

#### PRICAIN 2% SOLUTION FOR I.V. INJECTION

VOLUME	20 ml x 1 Vials	
PACKAGING	VIAL	Pricain 2% Soutcontrol V. bijection
ACTIVE INGREDIENT	Prilocaine HCI	Seeite - For investor
THERAPEUTIC FIELD	LOCAL ANESTHETIC	20 mi x 1 viat
CLINICAL USAGE	ANESTHESIA	

#### PROPOFOL-PF 1% 200 MG/20 ML EMULSION FOR INJECTION OR INFUSION

VOLUME	20 ml x 5 Ampoules	Propotol-PF %1
PACKAGING	AMPOULE	200 ma/20 ml
ACTIVE INGREDIENT	Propofol	20 ml x 5 annoutes
THERAPEUTIC FIELD	GENERAL ANESTHESIA	20 ml x 31
CLINICAL USAGE	ANESTHESIA, INTENSIVE CARE	

#### PROPOFOL-PF 1% 200 MG/20 ML EMULSION FOR INJECTION OR INFUSION

VOLUME	20 ml x 5 Ampoules	Propofol-PF %2
PACKAGING	AMPOULE	400 mg/2 v. Infection and for the second sec
ACTIVE INGREDIENT	Propofol	20 mi x 5 ampounts
THERAPEUTIC FIELD	GENERAL ANESTHESIA	20 ml x 5 ann
CLINICAL USAGE	ANESTHESIA, INTENSIVE CARE	

PROPOFOL-PF 2% 10	00 MG/50 ML EMULSION FOR INJECTION/INFUSION	
VOLUME	50 ml	
PACKAGING	VIAL	Propatol-PF 2% 1000 mg/50 mL Emulsion for LV. Injection/Influsion
ACTIVE INGREDIENT	Propofol	Presel Print Prin
THERAPEUTIC FIELD	GENERAL ANESTHESIA	50 mL x 1 viat
CLINICAL USAGE	ANESTHESIA, INTENSIVE CARE	

PROPOFOL-PF MCT 1% 500 MG/50 ML EMULSION FOR I.V. INJECTION/INFUSION				
VOLUME	50 ml			
PACKAGING	VIAL	Proposito PP MCT 194 Omgo Su C. Transformation for L.V. Insection/Infaunt		
ACTIVE INGREDIENT	Propofol	A cardinal sector and the sector and		
THERAPEUTIC FIELD	GENERAL ANESTHESIA	50 mL x1 viai		
CLINICAL USAGE	ANESTESIA, INTENSIVE CARE UNITS			

## PROPOFOL-PF MCT 1% 200 MG/20 ML I.V. EMULSION FOR INJECTION/INFUSION

INSECTION, IN OSIC			
VOLUME	20 ml x 5 Ampoules	Propofol-PF MCT 1%	
PACKAGING	AMPOULE	2 00 Miles for injections	
ACTIVE INGREDIENT	Propofol	20 mL S ampul	, 
THERAPEUTIC FIELD	GENERAL ANESTHESIA		
CLINICAL USAGE	ANESTHESIA, INTENSIVE CARE		

#### PROPOFOL-PF MCT 2% 1000 MG/50 ML EMULSION FOR I.V. INJECTION/INFUSION

VOLUME	50 ml	
PACKAGING	VIAL	Propolal-PF MCT 2% bob me/50 mit Emission for L.V. lejetion/Infusion
ACTIVE INGREDIENT	Propofol	And And And And And And And And And And
THERAPEUTIC FIELD	GENERAL ANESTHESIA	SO mL x 1 vial
CLINICAL USAGE	ANESTESIA, INTENSIVE CARE UNITS	

MUSCOBLOC 50 MG FOR I.V. INJECTION	/5 ML SOLUTION	<sup>2*</sup> Cold Chain Product		
VOLUME	5 ml x 5 Vials / 10 Vials			
PACKAGING	VIAL		Muscobioc 50 mq/5 ml Solution For LVL highertion	
ACTIVE INGREDIENT	Rocuronium Bromide		Smir 5 vides	The second secon
THERAPEUTIC FIELD	SKELETAL MUSCLE RELAXANT			
CLINICAL USAGE	ANESTHESIA, INTENSIVE CARE			

MUSCOBLOC 100 MG FOR I.V. INJECTION	G/10 ML SOLUTION	<sup>2</sup> ••••••Cold Chain Product		
VOLUME	10 ml x 10 Vials			
PACKAGING	VIAL		Muscobloc too mg/to ml Solution For LV. Injection	≍ /
ACTIVE INGREDIENT	Rocuronium Bromide	Transmission (Constraint)	Entrile LX, Harclon Water Bonnie K 10 vials K 10 vials	
THERAPEUTIC FIELD	Skeletal Muscle Relaxant			
CLINICAL USAGE	ANESTHESIA, INTENSIVE CARE			

SALERO 2,5 MG/2,5 M	1L INHALATION SOLUTION FOR NEBULIZATION	
VOLUME	2,5 ml x 20 Ampoules	Salero 2,5 mg/2,5 mL
PACKAGING	AMPOULE	
ACTIVE INGREDIENT	Salbutamol Sulfate	2.5 ml ( 20 Annual
THERAPEUTIC FIELD	BRONCHODILATOR	I mg(2.1) unggata tranggata tranggata
CLINICAL USAGE	RESPIRATORY TRACT DISEASES	

SEVONES 100% INHA	LATION SOLUTION	
VOLUME	250 ml	Sevones 100% inhaltion Sevofturane
PACKAGING	ALUMINIUM BOTTLE	
ACTIVE INGREDIENT	Sevoflurane	Sevenes Beneral Market
THERAPEUTIC FIELD	GENERAL ANESTESIA	250 mL 1 Auritoria Better Batteria
CLINICAL USAGE	ANESTESIA	

BRIMADEKS 200 MG,	/2 ML SOLUTION FOR I.V. INJECTION	
VOLUME	2 ml x 10 vials	
PACKAGING	VIAL	Brimadeks 200 mg/2 mL Solution for LV. Injection
ACTIVE INGREDIENT	Sugammadex	States for Introvenous Administration
THERAPEUTIC FIELD	REVERSAL OF NEUROMUSCULAR BLOCKAGE	
CLINICAL USAGE	ANESTHESIA	

BRIMADEKS 500 MG,	/5 ML SOLUTION FOR I.V. INJECTION	
VOLUME	5 ml x 10 vials	
PACKAGING	VIAL	Brimadeks soo m/ 5 mL Solution for I.V. Injection
ACTIVE INGREDIENT	Sugammadex	State-rich istamus schologion
THERAPEUTIC FIELD	REVERSAL OF NEUROMUSCULAR BLOCKAGE	
CLINICAL USAGE	ANESTHESIA	

TEİKOPOL 200 MG F I.M./I.V. INJECTION	POWDER AND SOLVENT FOR SOLUTION FOR	
DOSE	200 mg, 1 Lyophilized Vial + 1 Solvent Ampoule	
PACKAGING	VIAL	Subject for Subject for Telegraphic
ACTIVE INGREDIENT	Teicoplanin	Stafe (L_L)X and office
THERAPEUTIC FIELD	ANTIBACTERIAL	iteration
CLINICAL USAGE	INFECTIOUS DISEASES	

TEİKOPOL 400 MG F I.M./I.V. INJECTION	POWDER AND SOLVENT FOR SOLUTION FOR	
DOSE	400 mg, 1 Lyophilized Vial + 1 Solvent Ampoule	
PACKAGING	VIAL	Salidon for UAUX hypother Telepation
ACTIVE INGREDIENT	Teicoplanin	Sorier (UK):K referring
THERAPEUTIC FIELD	ANTIBACTERIAL	Foregram
CLINICAL USAGE	INFECTIOUS DISEASES	

TROCMETAM 20 MG	LYOPHILIZED POWDER FOR INJECTION	
DOSE	20 mg, 1 Lyophilized Vial + 1 Solvent Ampoule	
PACKAGING	VIAL	Lynakizad reserve re a provin
ACTIVE INGREDIENT	Tenoxicam	Terrer Ly / 2. weedsa
THERAPEUTIC FIELD	ANALGESIC, ANTI-INFLAMMATORY	Legendra Mar
CLINICAL USAGE	ALL CLINICS	

POLTEOFILIN 400 M	G/500 ML INJECTABLE SOLUTION FOR I.V. INFUSION	
VOLUME	500 ml	
PACKAGING	PP BAG	tation campaires and the second sec
ACTIVE INGREDIENT	Theophylline Anhydrus	<ul> <li>Beneficial de la destrucción de la</li></ul>
THERAPEUTIC FIELD	BRONCHODILATOR	A mendidament
CLINICAL USAGE	CHEST DISEASES	

POLTEOFILIN 200 M	G/100 ML INJECTABLE SOLUTION FOR I.V. INFUSION	
VOLUME	100 ml	
PACKAGING	PP BAG	The second secon
ACTIVE INGREDIENT	Theophylline Anhydrus	
THERAPEUTIC FIELD	BRONCHODILATOR	
CLINICAL USAGE	CHEST DISEASES	

TYGEPOL 50 MG LYO	PHILIZED POWDER FOR IV INFUSION SOLUTION	
DOSE	50 mg, 10 Vials	
PACKAGING	VIAL	
ACTIVE INGREDIENT	Tigecycline	50 mg Lypohlized Powder For Solution For IV, Iv Infusion Topezine 50 Vini 20mi - 1V, Infusion
THERAPEUTIC FIELD	ANTIBACTERIAL	
CLINICAL USAGE	INFECTIOUS DISEASES	

AGREDUR READY 50	MCG/ML SOLUTION FOR I.V. INFUSION	
VOLUME	100 ml, 250 ml	No.171.625 200 mil
PACKAGING	PP BAG	Line and the second sec
ACTIVE INGREDIENT	Tirofiban HCI	
THERAPEUTIC FIELD	ANTITHROMBOTIC	
CLINICAL USAGE	CARDIOLOGY	

## VANKOPOL 500 MG LYOPHILIZED POWDER FOR SOLUTION FOR I.V. INFUSION AND ORAL USE

DOSE	500 mg, 1 Lyophilized Vial	Van Koppol Soon u sponter Invester le station for
PACKAGING	VIAL	U. Underson AC Oral Date Vancemych HCI
ACTIVE INGREDIENT	Vancomycin Hydrochloride	Sterife Ly, Indiaton, ere cond.
THERAPEUTIC FIELD	ANTIBACTERIAL	
CLINICAL USAGE	INFECTIOUS DISEASES	

VANKOPOL 1000 MC I.V. INFUSION AND C	S LYOPHILIZED POWDER FOR SOLUTION FOR DRAL USE	
DOSE	1000 mg, 1 Lyophilized Vial	Vankopol
PACKAGING	VIAL	New York States for U. Historia do Grupo Vaccompile MC
ACTIVE INGREDIENT	Vancomycin Hydrochloride	Sterio U: hiddow U: we think call fact or or of Uter at the call fact or of the think of the the the the the the the the the the
THERAPEUTIC FIELD	ANTIBACTERIAL	
CLINICAL USAGE	INFECTIOUS DISEASES	

VECUBLOC 10 MG IV FOR I.V. INJECTION	POWDER AND SOLVENT FOR PREPARING SOLUTION	
DOSE	10 mg Lyophilized Vial + 1 Solvent Ampoule	
PACKAGING	VIAL	Vecubloc
ACTIVE INGREDIENT	Vecuronium Bromide	To mg Power and South for In Program South for In Vecuration Frender Vecuration Frender
THERAPEUTIC FIELD	Skeletal Muscle Relaxant	12 months in the second se
CLINICAL USAGE	ANESTHESIA, INTENSIVE CARE	

VORİKANDİN 200 MO	IV POWDER FOR SOLUTION FOR I.V. INFUSION	
DOSE	200 mg, 1 Lyophilized Vial	Vorikandin Dorre Den fri Salan
PACKAGING	VIAL	Vericonazole
ACTIVE INGREDIENT	Voriconazole	For KL Hilden
THERAPEUTIC FIELD	ANTIFUNGAL	
CLINICAL USAGE	INFECTIOUS DISEASES	

OSSI 4 MG/5 ML CON	CENTRATED SOLUTION FOR I.V. INFUSION	
VOLUME	5 ml x 1 Vial	Ossi 4 mg/5 ml
PACKAGING	VIAL	Concentral Solution for I.V. Infusion
ACTIVE INGREDIENT	Zoledronic Acid Monohydrate	Concentrated Solution V. Induced V. Induced
THERAPEUTIC FIELD	BONE LOSS TREATMENT DUE TO CHEMOTHERAPY	
CLINICAL USAGE	BISPHOSPHONATE	



🖀 POLİFARMA

# **3-CHAMBER BAG NUTRITIONAL SOLUTIONS**

#### POLINUTHREE EN-550 AMINO ACID SOLUTION WITH ELECTROLYTE, GLUCOSE SOLUTION AND LIPID EMULSION

					Franci	
VOLUME	1000 ml, 1500 ml, 2000 ml	/	Annual Lines A Dansan Annual A Dansan Annual A Dansan Annual A Dansan Annual A Dansan Annual A Dansan Annual A Dansan	POLINUTHREE EN-550 Ministration of Ministration Ministration of Ministration Ministration of Ministration Ministration of Ministration	Lange and the second se	
PACKAGING	PP BAG		Andre State	Names and a second se	And And And And And And And And And And	
ACTIVE INGREDIENT	L-Leucine, L-Alanine, L-Arginine, L-Isoleucine Glycine L-Proline, L-Phenylalanine, L-Lysine Hydrochloride L-Methionine, L-Valine, L-Serine, L-Tyrosine, L-Tryptophan, L-Threonine, Sodium Acetate Trihydrate, Sodium Glycerophosphate Pentahydrate, Potassium Chloride, Magnesium Chloride Hexahydrate, Glucose, Calcium Chloride Dihydrate, Refined Olive Oil, Refined Soybean			runor		
THERAPEUTIC FIELD	PARENTERAL NUTRITION					

Da a on

## POLINUTHREE EN-1000 AMINO ACID SOLUTION WITH ELECTROLYTE, GLUCOSE SOLUTION AND LIPID EMULSION

VOLUME PACKAGING	1000 ml, 1500 ml, 2000 ml PP BAG	
ACTIVE INGREDIENT	L-Leucine, L-Alanine, L-Arginine, L-Isoleucine Glycine L-Proline, L-Phenylalanine, L-Lysine Hydrochloride L-Methionine, L-Valine, L-Serine, L-Tyrosine, L-Tryptophan, L-Threonine, Sodium Acetate Trihydrate, Sodium Glycerophosphate Pentahydrate, Potassium Chloride, Magnesium Chloride Hexahydrate, Glucose, Calcium Chloride Dihydrate, Refined Olive Oil, Refined Soybean	
THERAPEUTIC FIELD	PARENTERAL NUTRITION	

## LIPID EMULSION

OLIVIA 20% LIPID EN	IULSION FOR I.V. INFUSION	
VOLUME	500 ml	MOREST 100 ML €00000 OLIVIA 20% ™ UPD BULGEON MONTON WERE ANTIMICATIONNO
PACKAGING	PP BAG	THUS. ADDRESS of the
ACTIVE INGREDIENT	Refined Olive Oil, Refined Soybean Oil	
THERAPEUTIC FIELD	PARENTERAL NUTRITION	

REXOMEGA-3 10 G/10	DO ML INFUSION EMULSION	
VOLUME	100 ml	100 mt (2000) RECORDERANCE of a yron as Marketing of the first of a second seco
PACKAGING	PP BAG	A second se
ACTIVE INGREDIENT	Fish Oil	
THERAPEUTIC FIELD	PARENTERAL NUTRITION	

## **AMINO ACID SOLUTIONS**

PF HIPERALAMINE 10	0% AMINO ACID SOLUTION FOR I.V. INFUSION	因
VOLUME	500 ml, 1000 ml	
PACKAGING	GLASS BOTTLE	
ACTIVE INGREDIENT	L-Isoleucine, L-Leucine, L-Lysine acetate, L-Methionine, L-Phenylalanine, L-Threonine, L-Tryptophan, L-Valine, L-Alanine, L-Arginine, L-Histidine, Glycine, L-Cysteine HCl, L-Proline, L-Serine	
THERAPEUTIC FIELD	PARENTERAL NUTRITION	

PF HIPERALAMINE 8	.5% AMINO ACID SOLUTION FOR I.V. INFUSION	R
VOLUME	500 ml, 1000 ml	
PACKAGING	GLASS BOTTLE	
ACTIVE INGREDIENT	L-İsoleucine, L-leucine, L-Lysine acetate, L-Methionine, L-Phenylalanine, L-Threonine, L-Tryptophan, L-Valine, L-Alanine, L-Arginine, L-Histidine, Glycine, L-Cysteine HCl, L-proline, L-Serine	

#### THERAPEUTIC FIELD PARENTERAL NUTRITION

PF K-CAMINE 8% AM	INO ACID SOLUTION FOR I.V. INFUSION	R
VOLUME	500 ml, 1000 ml	
PACKAGING	GLASS BOTTLE	Soo mi     Proceeding of the source of
ACTIVE INGREDIENT	L-İsoleucine, L-Leucine, L-Lysine acetate, L-Methionine,L-Phenylalanine, L-Threonine, L-Tryptophan, L-Valine, L-Alanine, L-Arginine, L-Histidine, Glycine, L-Cysteine HCl, L-Proline, L-Serine	
THERAPEUTIC FIELD	PARENTERAL NUTRITION	

PF NEPHRICAMINE 5	.4% AMINO ACID SOLUTION FOR I.V. INFUSION	R
VOLUME	500 ml	
PACKAGING	GLASS BOTTLE	The real Control of the real o
ACTIVE INGREDIENT	L-İsoleucine, L-Leucine, Lysine, L-Methionine, L-Phenylalanine, L-Threonine, L-Tryptophan, L-Valine, L-Cysteine hydrochloride dihydrate, L-Histidine, L-Tyrosine, L-Alanine, L-Arginine, Glycine, L-Aspartic acid, L-Glutamic acid, Taurine	
THERAPEUTIC FIELD	PARENTERAL NUTRITION	

PF PEDIATRIAMINE	5% AMINO ACID SOLUTION FOR I.V. INFUSION	R
VOLUME	500 ml	
PACKAGING	GLASS BOTTLE	The second secon
ACTIVE INGREDIENT	L-İsoleucine, L-Leucine, Lysine, L-Methionine, L-Phenylalanine, L-Threonine, L-Tryptophan, L-Valine, L-Cysteine hydrochloride dihydrate, L-Histidine, L-Tyrosine, L-Alanine, L-Arginine, Glycine, L-Aspartic acid, L-Glutamic acid, Taurine, L-Proline, L-Serine	
THERAPEUTIC FIELD	PARENTERAL NUTRITION	

PF TRAUMATICAMIN	E 6.9% AMINO ACID SOLUTION FOR I.V. INFUSION	R
VOLUME	500 ml, 1000 ml	
PACKAGING	GLASS BOTTLE	
ACTIVE INGREDIENT	L-Isoleucine, L-leucine, Lysine, L-Methionine, L-Phenylalanine, L-Threonine, L-Valine, L-Alanine, L-Arginine, L-Histidine, Glycine, Cysteine, L-Proline, L-Serine, L-Trytophan	
THERAPEUTIC FIELD	PARENTERAL NUTRITION	



A POLIFARMA

# **BASIC (STANDARD) I.V. SOLUTIONS**

POLIFLEKS 0.45% SC	DOIUM CHLORIDE I.V. SOLUTION FOR INFUSION	
VOLUME	100 ml, 150 ml, 250 ml, 500 ml, 1000 ml	1042FURST 500 mm GARMENT 0.45% SODUM CHLORIDE 350.0000 M L MUSICK 10444.1.499/808
PACKAGING	PP BAG	Lea 19 Au onzer 16 Au 19 Au 19 Au 19 Au 19 Au 19 Au August 19 August 19 August 19 Au August 19 August 1
ACTIVE INGREDIENT	Sodium Chloride	<ul> <li>and a constraint of the start o</li></ul>
CATEGORY	BASIC SOLUTIONS	

POLIFLEKS 0.9% ISO	TONIC SODIUM CHLORIDE SOLUTION FOR I.V. INFU	SION
VOLUME	50 ml, 100 ml, 150 ml, 250 ml, 500 ml, 1000 ml, 3000 ml, 5000 ml	
PACKAGING	PP BAG	B) the track head of the second se
ACTIVE INGREDIENT	Sodium chloride	under standing für der
CATEGORY	BASIC SOLUTIONS	

PF 0.9% ISOTONIC SO	ODIUM CHLORIDE SOLUTION FOR I.V. INFUSION	R
VOLUME	500 ml, 1000 ml	
PACKAGING	GLASS BOTTLE	100 mm Communication
ACTIVE INGREDIENT	Sodium chloride	<ul> <li>The standard stan</li></ul>
CATEGORY	BASIC SOLUTIONS	

POLIFLEKS 3% HYPEI	RTONIC SODIUM CHLORIDE SOLUTION FOR I.V. INF	
VOLUME	100 ml, 150 ml, 250 ml, 500 ml, 1000 ml	AND THE CONTRACT OF THE CONTRACT. THE CONTRACT OF THE CONTRACT OF THE CONTRACT OF THE CONTRACT OF THE CONTRACT OF THE CONTRACT OF THE CONTRACT OF THE CONTRACT. THE CONTRACT OF THE CONTRACT OF THE CONTRACT OF THE CONTRACT. THE CONTRACT OF THE CONTRACT OF
PACKAGING	PP BAG	But State     But State
ACTIVE INGREDIENT	Sodium Chloride	<ul> <li>The main line is a description of the main line is a descript</li></ul>
CATEGORY	BASIC SOLUTIONS	
	·	

## PF 3% HYPERTONIC SODIUM CHLORIDE SOLUTION FOR I.V. INFUSION

VOLUME	500 ml, 1000 ml	7	
PACKAGING	GLASS BOTTLE		500 ml
ACTIVE INGREDIENT	Sodium chloride		There to depend a many sectors and the sector of the secto
CATEGORY	BASIC SOLUTIONS		

#### POLIFLEKS 5% DEXTROSE SOLUTION FOR I.V. INFUSION

VOLUME	50 ml, 100 ml, 150 ml, 250 ml, 500 ml, 1000 ml	50 UTO FOR IL NEURISON	
PACKAGING	PP BAG	20     30     30     40	
ACTIVE INGREDIENT	Dextrose Anhydrus	end constraints of the constr	
CATEGORY	BASIC SOLUTIONS		

~

~

#### PF 5% DEXTROSE SOLUTION FOR I.V. INFUSION

VOLUME	500 ml, 1000 ml	
PACKAGING	GLASS BOTTLE	
ACTIVE INGREDIENT	Dextrose Anhydrus	
CATEGORY	BASIC SOLUTIONS	

#### POLIFLEKS 10% DEXTROSE SOLUTION FOR I.V. INFUSION

		POLIFICES' 500 mm	
VOLUME	100 ml, 150 ml, 250 ml, 500 ml, 1000 ml	10% DEXTROSE SOLUTION FOR LV. INFUSION STRIKE - LV. RAVISON	
PACKAGING	PP BAG	188 Start Start another in the start and start and start and start and start in the start and start and start and start and start in the start and start and start and start and start and start and start and start and start and start and another in the start and start and start and start and another in the start and start and start and start and another in the start and start and start and start and another in the start and start and start and start and another in the start and start and start and start and another in the start and start and start and start and another in the start and start and start and start and another in the start and start and start and start and another in the start and start and start and start and another in the start and start and start and another in the start and start and start and another in the start and start and another in the start and start and another in the start and start and another in the start and start and another in the start and start and another in the start and start and another in the start and start and another in the start and start and another in the start and start and another in the start and start and another in the start and start and another in the start and start and another in the start and start and another in the start and start and another in the start and start and another in the start and start and another in the start and start and another in the start and another in the start and another in the start and another in the start and another in the start and another in the start and another in the start and another in the start another in the start and another in the start and another in the start and another in the start another in the start another in the start and another in the start and another in the start and another in the start another in the start and another in the start and another in the start another in the start another in the start and another in the start and another in the start another in the start another in the start another in t	/
ACTIVE INGREDIENT	Dextrose Anhydrus	and strategies detailed and strategies and strategies detailed and strategies and strategies detailed and strategies and strategies detailed and strategies and strategies detailed and strategies and strategies detailed and strategies and strategies detailed and strat	
CATEGORY	BASIC SOLUTIONS		
			/

PF 10% DEXTROSE SC	DLUTION IN WATER FOR I.V. INFUSION		R	
VOLUME	500 ml, 1000 ml			
PACKAGING	GLASS BOTTLE		S00 mt PF 10% DEXTROSS CULTOR FOR IX, INFUSION CULTOR FOR IX, INFOS	/
ACTIVE INGREDIENT	Dextrose Anhydrus		The second secon	
CATEGORY	BASIC SOLUTIONS		a more at	

#### POLIFLEKS 20% DEXTROSE SOLUTION FOR I.V. INFUSION

VOLUME	100 ml, 150 ml, 250 ml, 500 ml, 1000 ml	POINTS 500 MI CARANTA Points 20 % DEXTROSE =Solution For LV, INFUSION URBALLA MENUSION
PACKAGING	PP BAG	Buyers and a constraints     Buyers and
ACTIVE INGREDIENT	Dextrose Anhydrus	<ul> <li>Section and a section and a section at a sec</li></ul>
CATEGORY	BASIC SOLUTIONS	

#### PF 20% DEXTROSE SOLUTION IN WATER FOR I.V. INFUSION

VOLUME	500 ml		
PACKAGING	GLASS BOTTLE	DO mit (Fyram) PPE 20 % DEXTROSS Statistic for the instruction	
ACTIVE INGREDIENT	Dextrose Anhydrus	A state of the	
CATEGORY	BASIC SOLUTIONS		

#### POLIFLEKS 30% DEXTROSE SOLUTION FOR I.V INFUSION

VOLUME	100 ml, 150 ml, 250 ml, 500 ml, 1000 ml	Sacras San San San San San San San San San San	
PACKAGING	PP BAG	East tota unitary     W1     East tota unitary     W1     East tota unitary     W1     East tota unitary     W1     East tota unitary	
ACTIVE INGREDIENT	Dextrose Anhydrus	<ul> <li>and register allowing of the second se</li></ul>	
CATEGORY	BASIC SOLUTIONS		

#### PF 30% DEXTROSE SOLUTION IN WATER FOR I.V. INFUSION

VOLUME	250 ml, 500 ml	7			
PACKAGING	GLASS BOTTLE			COM INTERNATION	
ACTIVE INGREDIENT	Dextrose Anhydrus			Will Marche Consumptions: 1688 about. Not are retained to the consumption of the consu	/
CATEGORY	BASIC SOLUTIONS		in the		

POLIFLEKS 50% DEX	TROSE SOLUTION FOR I.V. INFUSION	
VOLUME	100 ml, 150 ml, 250 ml, 500 ml, 1000 ml	500 ML CARTER
PACKAGING	PP BAG	BUTLE-14 APRICED      BUTLE-14 APRICED
ACTIVE INGREDIENT	Dextrose Anhydrus	<ul> <li>The start of the s</li></ul>
CATEGORY	BASIC SOLUTIONS	Prevent frames



#### PF 50% DEXTROSE SOLUTION FOR I.V. INFUSION

VOLUME	500 ml, 1000 ml		
PACKAGING	GLASS BOTTLE	S00 mt Frame	
ACTIVE INGREDIENT	Dextrose Anhydrus	<ul> <li>In the second sec</li></ul>	
CATEGORY	BASIC SOLUTIONS		

-

~

## POLIFLEKS 5% DEXTROSE - 0.2% SODIUM CHLORIDE SOLUTION FOR I.V. INFUSION

VOLUME	100 ml, 150 ml, 250 ml, 500 ml, 1000 ml	10.2014/2017 500 mil Carolina 5% DEXTROSE 0.2% SODIUM CHLORIDE DEML-1-14 MIRION
PACKAGING	PP BAG	M (a) All or contents and an advanced and a set of a new bit particular of a set of a memory of a particular of a set of a set of a memory of a set of a set of a set of a set of a memory of a set of a set of a set of a set of a memory of a set of a set of a set of a set of a memory of a set of a set of a set of a set of a real set of a set of a set of a set of a set of a set of a real set of a set of a set of a set of a set of a set of a real set of a set of a set of a set of a set of a set of a real set of a set of a set of a set of a set of a set of a real set of a set of a set of a set of a set of a set of a real set of a set of a set of a set of a set of a set of a real set of a set of a set of a set of a set of a set of a real set of a set of a set of a set of a set of a set of a real set of a set of a set of a set of a set of a set of a real set of a set of a set of a set of a set of a set of a real set of a set of a set of a set of a set of a set of a real set of a set of a set of a set of a set of a set of a real set of a set of a set of a set of a set of a set of a real set of a set of a set of a set of a set of a set of a real set of a set of a set of a set of a set of a set of a set of a real set of a s
ACTIVE INGREDIENT	Dextrose Anhydrus, Sodium Chloride	The lipse and region with a distance and the second sec
CATEGORY	BASIC SOLUTIONS	Promethanus (Prosectivation

PF 5% DEXTROSE 0.2	2% SODIUM CHLORIDE SOLUTION FOR I.V. INFUSION		R	
VOLUME	500 ml, 1000 ml	7		
PACKAGING	GLASS BOTTLE		Soo mi     Contraction	
ACTIVE INGREDIENT	Dextrose Monohydrate, Sodium Chloride		The second secon	
CATEGORY	BASIC SOLUTIONS			

## POLİFLEKS 5% DEXTROSE - 0.45% SODIUM CHLORIDE SOLUTION FOR I.V. INFUSION

VOLUME	250 ml, 500 ml, 1000 ml
PACKAGING	PP BAG
ACTIVE INGREDIENT	Dextrose Anhydrus, Sodium Chloride
CATEGORY	BASIC SOLUTIONS

PF 5% DEXTROSE 0.4	45% SODIUM CHLORIDE SOLUTION FOR I.V. INFUSION		尺	
VOLUME	500 ml, 1000 ml	7		
PACKAGING	GLASS BOTTLE		500 ml	
ACTIVE INGREDIENT	Dextrose Monohydrate, Sodium Chloride		Bank State St	
CATEGORY	BASIC SOLUTIONS			

POLIFLEKS 5% DEXT	ROSE - 0.9% SODIUM CHLORIDE SOLUTION FOR I.V.	
VOLUME	250 ml, 500 ml, 1000 ml	Pouriers 300 mil      Dimension     S % DEXTROSE     = 0.9 % SODIUM CHLORIDE     Eodorer Kont V sources
PACKAGING	PP BAG	<ul> <li>Market of spaces, sp Kan be a specific of the space of the space of the space Kan be a specific of the space of the space of the space Kan be a specific of the space of the space of the space of the space Kan be a specific of the space of the</li></ul>
ACTIVE INGREDIENT	Dextrose Monohydrate, Sodium Chloride	<ul> <li>The second</li></ul>
CATEGORY	BASIC SOLUTIONS	

<b>DE 5% DEXTROSE 0 9%</b>	SODIUM CHI OPIDE	SOLUTION FOR I.V. INFUSION

PF 5% DEXTROSE 0.99	% SODIUM CHLORIDE SOLUTION FOR I.V. INFUSION	R
VOLUME	500 ml, 1000 ml	
PACKAGING	GLASS BOTTLE	500 mt Province 5 % DEXTROSE 0.9 %
ACTIVE INGREDIENT	Dextrose Monohydrate, Sodium Chloride	<ul> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Section 2014</li> <li>Secti</li></ul>
CATEGORY	BASIC SOLUTIONS	A Marger at the second se

PF 5% DEXTROSE 0. SOLUTION FOR I.V. I	45% SODIUM CHLORIDE 0.3% POTASSIUM CHLORIDE NFUSION	尺
VOLUME	500 ml, 1000 ml	
PACKAGING	GLASS BOTTLE	Stormal Constant of the second
ACTIVE INGREDIENT	Dextrose Monohydrate, Sodium Chloride, Potassium Chloride	The second secon
CATEGORY	BASIC SOLUTIONS	Construction of the second sec

## POLİFLEKS 5% DEXTROSE - 0.45% SODIUM CHLORIDE - 0.3% POTASSIUM CHLORIDE SOLUTION FOR I.V. INFUSION

VOLUME	250 ml, 500 ml, 1000 ml	
PACKAGING	PP BAG	
ACTIVE INGREDIENT	Dextrose Monohydrate, Sodium Chloride, Potassium Chloride	
CATEGORY	BASIC SOLUTIONS	

POLIFLEKS 1/3 POLI SOLUTION FOR I.V. I	DEX (3.33% DEXTROSE-0.3% SODIUM CHLORIDE) NFUSION	
VOLUME	100 ml, 150 ml, 250 ml, 500 ml, 1000 ml	1/3 POLIDEKS
PACKAGING	PP BAG	EVER.4.4.4.4.4.6. We have a particular of the
ACTIVE INGREDIENT	Dextrose Anhydrus, Sodium Chloride	<ul> <li>The first parameter framework is the first parameter</li></ul>
CATEGORY	BASIC SOLUTIONS	
	·	

INFUSION	3% DEXTROSE-0.3% SODIUM CHLORIDE) SOLUTION FOR	
VOLUME	500 ml, 1000 ml	
PACKAGING	GLASS BOTTLE	
ACTIVE INGREDIENT	Dextrose Anhydrus, Sodium Chloride	Image: Section 1         Image: Section 2           Image: Section 2
CATEGORY	BASIC SOLUTIONS	

PF 1/4 POLIDEKS (% FOR I.V. INFUSION	3.75 DEXTROSE %0.225 SODIUM CHLORIDE) SOLUTION	R
VOLUME	500 ml, 1000 ml	
PACKAGING	GLASS BOTTLE	Soo mt     Choras     PF 1/14 POLIDEKS     Prime Management     Prime Management
ACTIVE INGREDIENT	Dextrose Anhydrus, Sodium Chloride	The second
CATEGORY	BASIC SOLUTIONS	

# **MULTIPLE ELECTROLYTE SOLUTIONS**

#### POLIFLEKS 5% DEXTROSE LACTATED RINGER SOLUTION FOR I.V. INFUSION

VOLUME	100 ml, 150 ml, 250 ml, 500 ml,  1000 ml	7
PACKAGING	PP BAG	
ACTIVE INGREDIENT	Sodium Chloride, Dextrose Monohydrate, Potassium Chloride, Calcium Chloride Dihydrate, Sodium Lactate	
CATEGORY	ELECTROLYTE SOLUTIONS	

VOLUME       500 ml, 1000 ml         PACKAGING       GLASS BOTTLE         ACTIVE INGREDIENT       Sodium Chloride, Potassium Chloride, Calcium Chloride Dihydrate, Sodium Lactate, Dextrose Monohydrate         CATEGORY       ELECTROLYTE SOLUTIONS	PF 5% DEXTROSE LA	CTATED RINGER SOLUTION FOR I.V. INFUSION		尺	
ACTIVE INGREDIENT         Sodium Chloride, Potassium Chloride, Calcium Chloride           Dihydrate, Sodium Lactate, Dextrose Monohydrate         Image: Calcium Chloride	VOLUME	500 ml, 1000 ml	7		
Dihydrate, Sodium Lactate, Dextrose Monohydrate	PACKAGING	GLASS BOTTLE		200 ml C53% DEXTROSE LACYALIS ANGO C55% DEXTROSE LACYALIS ANGO CUTION FOR IV INFUSION WITH COMPANY AND AND AND AND AND AND AND AND AND AND	
Concentration of the second second second second second second second second second second second second second	ACTIVE INGREDIENT				
	CATEGORY	ELECTROLYTE SOLUTIONS			

5 % DEXTROS

POLIFLEKS 20% MAN	INITOL SOLUTION FOR I.V. INFUSION	
VOLUME	100 ml, 150 ml, 250 ml, 500 ml, 1000 ml	1207200 100 100 100 100 100 100 100 100 100
PACKAGING	PVC/PP BAG	the star star star star star star star star
ACTIVE INGREDIENT	Mannitol	is the set of the set
CATEGORY	ELECTROLYTE SOLUTIONS	

PF 20% MANNITOL S	OLUTION FOR I.V. INFUSION	R
VOLUME	500 ml, 1000 ml	
PACKAGING	GLASS BOTTLE	
ACTIVE INGREDIENT	Mannitol	
CATEGORY	ELECTROLYTE SOLUTIONS	

POLIFLEKS IZOLEN E	BALANCED ELECTROLYTE SOLUTION FOR I.V. INFUSIO	
VOLUME	500 ml, 1000 ml	International Statement
PACKAGING	PP BAG	<ul> <li>Comparison of the second</li></ul>
ACTIVE INGREDIENT	Sodium Acetate Trihydrate, Sodium Chloride, Trisodium Citrate Dihydrate, Calcium Chloride Dihydrate, Potassium Chloride, Magnesium Chloride Hexahydrate	
CATEGORY	ELECTROLYTE SOLUTIONS	

PF IZOLEN BALANCE	ED ELECTROLYTE SOLUTION FOR I.V. INFUSION	R	
VOLUME	500 ml, 1000 ml		
PACKAGING	GLASS BOTTLE		
ACTIVE INGREDIENT	Sodium Acetate Trihydrate, Sodium Chloride, Sodium Citrate Dihydrate, Calcium Chloride Dihydrate, Potassium Chloride, Magnesium Chloride Hexahydrate		
CATEGORY	ELECTROLYTE SOLUTIONS		

## POLIFLEKS IZOLEN-M 5% DEXTROSE SOLUTION FOR I.V. INFUSION

VOLUME	250 ml, 500 ml, 1000 ml	
PACKAGING	PP BAG	
ACTIVE INGREDIENT	Dextrose Anhydrus, Sodium Acetate Trihydrate, Potassium Chloride, Dibasic Potassium Phosphate, Sodium Chloride	
CATEGORY	ELECTROLYTE SOLUTIONS	

PF IZOLEN-M 5% DEX	XTROSE SOLUTION FOR I.V. INFUSION	R
VOLUME	500 ml, 1000 ml	
PACKAGING	GLASS BOTTLE	500 mail CP 2000 PF 1220EAL 81 S % DEXTRO3 Pr 1220EAL 81 S % DEXTRO3 Pr 1220EAL 81 S % DEXTRO3 Pr 1220EAL 81 S % DEXTRO3
ACTIVE INGREDIENT	Dextrose Monohydrate, Sodium Acetate Trihydrate, Potassium Chloride, Dibasic Potassium Phosphate, Sodium Chloride	
CATEGORY	ELECTROLYTE SOLUTIONS	

POLİFLEKS IZOLEN-P 5	% DEXTROSE ELECTROLYTE SOLUTION FOR I.V INFUSIO	
VOLUME	250 ml, 500 ml, 1000 ml	izolen-p izolen-p 5% Dextractions Licenser
PACKAGING	PP BAG	<ul> <li>The second</li></ul>
ACTIVE INGREDIENT	Dextrose Monohydrate, Sodium Lactate, Potassium Chloride, Dibasic Potassium Phosphate, Magnesium Chloride Hexahydrate, Sodium Bisulfite	
CATEGORY	ELECTROLYTE SOLUTIONS	

PF IZOLEN-P 5% DEX	TROSE SOLUTION FOR I.V. INFUSION	R
VOLUME	500 ml, 1000 ml	
PACKAGING	GLASS BOTTLE	600 mil ## million PrizoLanue # Sty DextRold PrizoLanue # Sty DextRold PrizoLanue # Sty DextRold PrizoLanue # Sty DextRold PrizoLanue # Sty DextRold PrizoLanue # Sty DextRold PrizoLanue PrizoLanue # Sty DextRold PrizoLanue
ACTIVE INGREDIENT	Dextrose Monohydrate, Sodium Lactate, Potassium Chloride, Magnesium Chloride Hexahydrate, Dibasic Potassium Phosphate	
CATEGORY	ELECTROLYTE SOLUTIONS	

120LEN-M 500 ml Paramet 120LEN-M 5% DEXTROSE SOLUTION FOR LX, INFUSION

۵**۱۱۱۱** 

POLIFLEKS IZOLEN- INFUSION	S PH 7.4 ELECTROLYTE SOLUTION FOR I.V.	
VOLUME	500 ml, 1000 ml	Internet Son Statistic isource and the son Son Son Son Son Son Son Son Son Son S
PACKAGING	PP BAG	<ul> <li>Section 2. Section 2</li></ul>
ACTIVE INGREDIENT	Sodium Chloride, Potassium Chloride, Sodium Acetate Trihydrate, Sodium Gluconate, Monobasic Potassium Phosphate, Magnesium Chloride Hexahydrate, Dibasic Sodium Phosphate Heptahydrate	HALF AND AND AND AND AND AND AND AND AND AND
CATEGORY	ELECTROLYTE SOLUTIONS	44

POLIFLEKS LACTATE	D RINGER SOLUTION FOR I.V. INFUSION	
VOLUME	100 ml, 150 ml, 250 ml, 500 ml, 1000 ml, 2000 ml	
PACKAGING	PP BAG	<ul> <li>Event and the second sec</li></ul>
ACTIVE INGREDIENT	Sodium Chloride, Calcium Chloride Dihydrate, Potassium Chloride, Sodium Lactate	
CATEGORY	ELECTROLYTE SOLUTIONS	

VOLUME       500 ml, 1000 ml         PACKAGING       GLASS BOTTLE         ACTIVE INGREDIENT       Sodium Chloride, Calcium Chloride Dihydrate, Potassium Chloride, Sodium Lactate         CATEGORY       ELECTROLYTE SOLUTIONS	PF LACTATED RINGE	R SOLUTION FOR I.V. INFUSION	R
ACTIVE INGREDIENT         Sodium Chloride, Calcium Chloride Dihydrate, Potassium Chloride, Sodium Lactate	VOLUME	500 ml, 1000 ml	
ACTIVE INGREDIENT Potassium Chloride, Sodium Lactate	PACKAGING	GLASS BOTTLE	Storms Constant Starting
CATEGORY ELECTROLYTE SOLUTIONS	ACTIVE INGREDIENT		
	CATEGORY	ELECTROLYTE SOLUTIONS	

## POLIFLEKS RINGER SOLUTION FOR I.V. INFUSION

VOLUME	500 ml, 1000 ml
PACKAGING	PP BAG
ACTIVE INGREDIENT	Sodium Chloride, Calcium Chloride, Potassium Chloride
CATEGORY	ELECTROLYTE SOLUTIONS



VOLUME500 ml, 100PACKAGINGGLASS BOT		
PACKAGING GLASS BO		
	TTLE	500 mt Crossan
ACTIVE INGREDIENT Sodium Ch Potassium	loride, Calcium Chloride Dihydrate, Chloride	
CATEGORY ELECTROL	YTE SOLUTIONS	

PRE-EKLAMOL MAGN	ESIUM SULFATE 4 G/100 ML I.V. INFUSION FOR SOLUTIO	
VOLUME	100 ml	THE CRUANING MADARETERS & ( 719 m
PACKAGING	PP BAG	The second secon
ACTIVE INGREDIENT	Magnesium Sulphate Heptahydrate	
CATEGORY	ELECTROLYTE SOLUTIONS	

PRE-EKLAMOL MAGI	NESIUM SULFATE 40 G/1000 ML SOLUTION FOR I.V.	
VOLUME	1000 ml	CUTURS 1000 ml Catomin PRE-RELANDIC MAGERSHIM SOLUTION FOR LC MORE SHIP SOLUTION FOR LC MORE SHIP
PACKAGING	PP BAG	deal     deal
ACTIVE INGREDIENT	Magnesium Sulphate Heptahydrate	<ul> <li>More and the second seco</li></ul>
CATEGORY	ELECTROLYTE SOLUTIONS	

VOLUME       1000 ml         PACKAGING       PP BAG         ACTIVE INGREDIENT       Calcium Chloride Dihydrate, Magnesium Chloride, Hexahydrate, Sodium Chloride, Potassium Chloride         CATEGORY       ELECTROLYTE SOLUTIONS	CARDIPASSIVE CARI	DIOPLEGIC SOLUTION FOR CARDIAC PERFUSION	
ACTIVE INGREDIENT Calcium Chloride Dihydrate, Magnesium Chloride, Hexahydrate, Sodium Chloride, Potassium Chloride	VOLUME	1000 ml	POLIT LOS TROVIET (MARTIN CARDIDALES) EN LOS CONTRACTOR CARDIDALES EN LOS CONTRACTOR CARDIDALES (CARDIDALES) EN LO
ACTIVE INGREDIENT Hexahydrate, Sodium Chloride, Potassium Chloride	PACKAGING	PP BAG	<ul> <li>and the second se</li></ul>
CATEGORY ELECTROLYTE SOLUTIONS	ACTIVE INGREDIENT		<ul> <li>The second</li></ul>
	CATEGORY	ELECTROLYTE SOLUTIONS	

## PLASMA VOLUME EXPANDER SOLUTIONS

POLİFLEKS 100 MG/ML DEXTRAN 40 - 9 MG/ML ISOTONIC SODIUM CHLORIDE SOLUTION FOR I.V. INFUSION

JOLOHON FOR I.V. I	NF03ION	
VOLUME	100 ml, 150 ml, 250 ml, 500 ml, 1000 ml	100 mg/ml DEXTRAN 40 = 9 mg/ml DEXTRAN 40 = 9 mg/ml DEXTRAN 40 = 10 mg/ml DEXTRAN 40 =
PACKAGING	PP BAG	Bit Chair and the set of the
ACTIVE INGREDIENT	Sodium Chloride, Dextran 40	10 the second
CATEGORY	PLASMA VOLUME COMPLEMENTARY SOLUTION	

### PF 100 MG/ML DEXTRAN 40 - 9 MG/ML ISOTONIC SODIUM CHLORIDE SOLUTION FOR I.V. INFUSION

VOLUME	500 ml, 1000 ml	
PACKAGING	GLASS BOTTLE	2 500 mt (2000) FF 100 mmg mm 10 EXTRAN (2000) With the second
ACTIVE INGREDIENT	Sodium Chloride, Dextran 40	<ul> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein auf Stranger (1998)</li> <li>Bernstein au</li></ul>
CATEGORY	PLASMA VOLUME COMPLEMENTARY SOLUTION	

200

## POLIFLEKS 60 MG/ML DEXTRAN 70 - 9 MG/ML ISOTONIC SODIUM CHLORIDE SOLUTION FOR I.V. INFUSION

VOLUME	500 ml, 1000 ml	60 mann DEXTRAN 70 90 mann DEXTRAN 70 90 mann DEXTRAN 70 10 mann DEXTRAN 70 10 mann 10 man
PACKAGING	PP BAG	<ul> <li>Manuscher Bergen, 1. Sing, 2. Sing,</li></ul>
ACTIVE INGREDIENT	Sodium Chloride, Dextran 70	
CATEGORY	PLASMA VOLUME COMPLEMENTARY SOLUTION	

PF 60 MG/ML DEXTI SOLUTION FOR I.V. I	RAN 70 - 9 MG/ML ISOTONIC SODIUM CHLORIDE NFUSION	R
VOLUME	500 ml, 1000 ml	
PACKAGING	GLASS BOTTLE	Constant Constan
ACTIVE INGREDIENT	Sodium Chloride, Dextran 70	<ul> <li>Here and the second seco</li></ul>
CATEGORY	PLASMA VOLUME COMPLEMENTARY SOLUTION	Nor ALL

PF POLIHES (HES 20	0/0.5) 6% SOLUTION FOR I.V. INFUSION	R
VOLUME	500 ml, 1000 ml	
PACKAGING	GLASS BOTTLE	500 ml Caratan PF POLIVES (VES 2000.5(5) MM AND AND AND AND AND AND AND AND AND AND
ACTIVE INGREDIENT	Hydroxyethyl Starch, Sodium Chloride	
CATEGORY	PLASMA VOLUME COMPLEMENTARY SOLUTION	

VOLUHES (HES 130/0	0.4) 6% I.V. SOLUTION FOR INFUSION	
VOLUME	500 ml	CULTURE SOUTH CANTERNAL CONTROL OF CONTROL O
PACKAGING	PP BAG	A sector of the sector of
ACTIVE INGREDIENT	Hydroxyethyl Starch, Sodium Chloride	<ul> <li>The second</li></ul>
CATEGORY	PLASMA VOLUME COMPLEMENTARY SOLUTION	

VOLIZOLEN (HES 130	0/0.4) 6% ELECTROLYTE SOLUTION FOR I.V. INFUSI	ON
VOLUME	500 ml	VOLUCION 90 mil Common VOLUCIOLEN (MARINA SOLOLA) Va accesso THE MARINA SOLOLA) Va accesso The Marina Sololada Marina Sololada
PACKAGING	PP BAG	""     "
ACTIVE INGREDIENT	Hydroxyethyl Starch, Sodium Chloride, Sodium Acetate Trihydrate, Potassium Chloride, Magnesium Chloride Hexahydrate	
CATEGORY	PLASMA VOLUME COMPLEMENTARY SOLUTION	

LIFE-EXTEND 60 MG SOLUTION FOR I.V. I	6/ML DEXTRAN 70 + 75 MG/ML SODIUM CHLORIDE NFUSION	
VOLUME	250 ml	POLITICAS 250 mT PROTOTO LIFE-EXTEND 600 mg/m DEXTRAN 70 + 75 mg/m DOUMD CHLORIDE
PACKAGING	PP BAG	SOLITON FOR IX. INTUSCON United to the soliton of
ACTIVE INGREDIENT	Dextran 70, Sodium Chloride	index in the other than the other the oth
CATEGORY	PLASMA VOLUME COMPLEMENTARY SOLUTION	the second



# **IRRIGATION SOLUTIONS**

PP STERILE DISTILL	ED WATER IRRIGATION SOLUTION	
VOLUME	500 ml, 1000 ml	In Progress
PACKAGING	PP BOTTLE	
CONTENT	Water for Injection	- Herner He Herner Her
CATEGORY	IRRIGATION SOLUTION	
MDR CLASS	IIB	

PF STERILE DISTILLE	ED WATER IRRIGATION SOLUTION	
VOLUME	500 ml, 1000 ml	In Progress
PACKAGING	GLASS BOTTLE	
CONTENT	Water for Injection	Owner         Owner         Owner           Owner         Owner         Owner           Owner         Owner         Owner           Owner         Owner         Owner           Owner         Owner         Owner           Owner         Owner         Owner           Owner         Owner         Owner           Owner         Owner         Owner           Owner         Owner         Owner           Owner         Owner         Owner           Owner         Owner         Owner
CATEGORY	IRRIGATION SOLUTION	
MDR CLASS	IIB	

VOLUME	50 ml, 100 ml, 150 ml, 250 ml, 500 ml, 1000 ml	
PACKAGING	PVC BAG	The second seco
CONTENT	Water for Injection	<ul> <li>For the second se</li></ul>
CATEGORY	IRRIGATION SOLUTION	
MDR CLASS	IIB	

PP BAG STERILE DIS	TILLED WATER IRRIGATION SOLUTION	
VOLUME	50 ml, 100 ml, 150 ml, 250 ml, 500 ml, 1000 ml	In Progress
PACKAGING	PP BAG	TERREE DISTILLED WATER BREATING STULLED WATER 2 DISTILL APPROACH Water Water Water Water Water Water Andread Andread Andread Andread Andread Andread Andread Andread Andread Andread Andread Breat Water Water Water Andread A
CONTENT	Water for Injection	The second secon
CATEGORY	IRRIGATION SOLUTION	
MDR CLASS	IIB	

#### PP ISOTONIC SODIUM CHLORIDE IRRIGATION SOLUTION

PP ISOTONIC SODIU	M CHLORIDE IRRIGATION SOLUTION	
VOLUME	500 ml, 1000 ml	In Progress
PACKAGING	PP BOTTLE	HISTORIC SOCIUL CRUSE BIGGIOL SOCIUL CRUSE BIGGIOL SOCIUL CRUSE UNIT SOLUTION
CONTENT	Sodium Chloride, Water for Injection	<ul> <li>The second</li></ul>
CATEGORY	IRRIGATION SOLUTION	
MDR CLASS	IIB	

BSS OCROSOL INTR SOLUTION)	AOCULAR IRRIGATION SOLUTION (BALANCED SALT	
VOLUME	500 ml, 1000 ml	In Progress
PACKAGING	GLASS BOTTLE	
CONTENT	Sodium Chloride, Potassium Chloride, Calcium Chloride, Sodium Acetate, Magnesium Chloride	
CATEGORY	INTRAOCULAR IRRIGATION SOLUTION	
MDR CLASS	IIB	

PVC BAG ISOTONIC	SODIUM CHLORIDE IRRIGATION SOLUTION	
VOLUME	250 ml, 350 ml, 500 ml, 750 ml, 850 ml, 1000 ml, 2000 ml, 3000 ml	CORRECT AND CONTROL OF A C
PACKAGING	PVC BAG	
CONTENT	Sodium Chloride, Water for Injection	- " the design of the design o
CATEGORY	IRRIGATION SOLUTION	
MDR CLASS	IIB	* *

PP BAG ISOTONIC S	ODIUM CHLORIDE IRRIGATION SOLUTION	
VOLUME	250 ml, 350 ml, 500 ml, 750 ml, 850 ml, 1000 ml, 2000 ml, 3000 ml	A state and the state and
PACKAGING	PP BAG	Construction of the second se
CONTENT	Sodium Chloride, Water for Injection	
CATEGORY	IRRIGATION SOLUTION	
MDR CLASS	ПВ	

POLIFLEKS 5% MAN	NITOL UROLOGIC IRRIGATION SOLUTION	
VOLUME	3000 ml	5 % MANNITOL BECOMMENTATION
PACKAGING	PVC BAG	■ The second se
CONTENT	Mannitol, Water for Injection	
CATEGORY	UROLOGIC IRRIGATION SOLUTION	
MDR CLASS	Ш	

POLIFLEKS 1.5% GLY	CINE UROLOGIC IRRIGATION SOLUTION	× ×
VOLUME	1500 ml, 2000 ml, 3000 ml	S S A CLOBE UNDLOG BRAITON SOLUTON BRAITON SOLUTON BRAITON SOLUTON BRAITON SOLUTON BRAITON
PACKAGING	PVC BAG	<ul> <li>Beneficial and the second secon</li></ul>
CONTENT	Glycine, Water for Injection	
CATEGORY	UROLOGIC IRRIGATION SOLUTION	• entrition and united
MDR CLASS	ш	

## **CATHETER LOCK SOLUTIONS**

CATESYT SODIUM CI	TRATE CATHETER LOCK SOLUTION 4%	
VOLUME	2,5 ml	In Progress
PACKAGING	BFS VIAL	
CONTENT	Trisodium Citrate Dihydrate, Water for Injection	
CATEGORY	CATHETER LOCK SOLUTION	Contrainer the second s
MDR CLASS	IIB	

CATESYT SODIUM CI	TRATE CATHETER LOCK SOLUTION 30%	
VOLUME	2,5 ml	In Progress
PACKAGING	BFS VIAL	
CONTENT	Trisodium Citrate Dihydrate, Water for Injection	
CATEGORY	CATHETER LOCK SOLUTION	in and the second second second second second second second second second second second second second second se
MDR CLASS	IIB	

CATESYT SODIUM CI	TRATE CATHETER LOCK SOLUTION 46.7%	
VOLUME	2,5 ml	In Progress
PACKAGING	BFS VIAL	
CONTENT	Trisodium Citrate Dihydrate, Water for Injection	
CATEGORY	CATHETER LOCK SOLUTION	diana and a second second second second second second second second second second second second second second s
MDR CLASS	IIB	

## **INFUSION SET**

POLI-SET INFUSION	SETS	MDR In Progress
PRODUCT TYPE	Luer Slip & Luer Lock	
STERILIZATION TYPE	GAMA Sterile & EO Sterile	The state management of the st
CATEGORY	INFUSION SET	
MDR CLASS	IIA	



A POLIFARMA

DEKSTROVIP 5% PER	FUSION SOLUTION	
VOLUME	500 ml, 1000 ml	
PACKAGING	PP BAG	
ACTIVE INGREDIENT	Dextrose Anhydrus	
CATEGORY	BASIC SOLUTION	

DEX-IZOVIP PERFUSI	ON SOLUTION	
VOLUME	500 ml, 1000 ml	
PACKAGING	PP BAG	<pre>Minimum 2</pre>
ACTIVE INGREDIENT	Dextrose Anhydrus, Sodium Chloride	<ul> <li>The second</li></ul>
CATEGORY	BASIC SOLUTION	T

ELECTROVIP PERFUS	SION SOLUTION	
VOLUME	500 ml, 1000 ml, 2000 ml	
PACKAGING	PP BAG	Image: Image:
ACTIVE INGREDIENT	Sodium Acetate Trihydrate, Sodium Chloride, Trisodium Citrate Dihydrate, Calcium Chloride Dihydrate, Potassium Chloride, Magnesium Chloride Hexahydrate	4 Control of the second
CATEGORY	ELECTROLYTE LOSS TREATMENT	

PACKAGING       PP BAG         ACTIVE INGREDIENT       Sodium Chloride, Calcium Chloride Dihydrate, Potassium Chloride, Sodium Lactate		
ACTIVE INGREDIENT Sodium Chloride, Calcium Chloride Dihydrate, Potassium Chloride, Sodium Lactate	VOLUME	
ACTIVE INGREDIENT Potassium Chloride, Sodium Lactate	PACKAGING	
	ACTIVE INGREDIENT	Ref. — Ref. = Re
CATEGORY ELECTROLYTE LOSS TREATMENT	CATEGORY	

IZOVIP PERFUSION S	OLUTION	
VOLUME	500 ml, 1000 ml, 5000 ml	
PACKAGING	PP BAG	<ul> <li>Be there are a set of the set o</li></ul>
ACTIVE INGREDIENT	Sodium Chloride	Control     Control       Control     Control
CATEGORY	BASIC SOLUTION	

DEKSTROVIP 30% PE		
VOLUME	500 ml, 1000 ml	
PACKAGING	PP BAG	<ul> <li>The second</li></ul>
ACTIVE INGREDIENT	Dextrose Anhydrus	Bern Stein St
CATEGORY	DUE TO CARBOHYDRATE DEFICIENCY PARENTERAL NUTRITION SOLUTION	

CALSI-VIP PERFUSIO	N SOLUTION	
VOLUME	500 ml	$7 \land )$
PACKAGING	GLASS BOTTLE	
ACTIVE INGREDIENT	Calcium Glucoheptonate, Magnesium chloride, Hexahydrate Dextrose anhydrus	
CATEGORY	TREATMENT OF CALCIUM AND MAGNESIUM DEFICIEN	

## **KALFOR-VIP INJECTION SOLUTION**

KALFOR-VIP INJECTI	ON SOLUTION	
VOLUME	500 ml	
PACKAGING	GLASS BOTTLE	
ACTIVE INGREDIENT	Calcium Gluconate Monohydrate, CalciumGlucoheptonate, Magnesium chloride, Hexahydrate Butafosfan	
CATEGORY	TREATMENT OF CALCIUM, MAGNESIUM AND PHOSPHORUS DEFICIENCY	

# 🔗 POLİFARMA



## AWARDED BY ALTIN HAVAN FOR 3<sup>rd</sup> TİME

Polifarma was awarded three times by Altın Havan; one in "Investment", one in "Social Responsibility" and one in 'Non-Medicine Innovation' categories.

## THE MOST TRUSTED FOOD SUPPLEMENT

Polifarma was awarded by "Feed the Future Awards" with its food supplement product ResQueen.



# Indext of the control of

## TURKEY'S FIRST INTRAVENOUS NEUROKININ-1

#### **BLOCKER**

We have produced the Intravenous NK-1 Blocker FOSEMAZON, one of the most effective drugs for preventing nausea and vomiting associated with high and moderate Emetogenic Cancer Chemotherapy in adults, pediatric patients 6 months of age and older.

FOSEMAZON, which emerged thanks to our extensive R&D studies and technological infrastructure, is produced only under the roof of Polifarma in Turkey. While nausea and vomiting complaints can be eliminated for 1-3 days with orally taken drugs, FOSEMAZON (Intravenous NK-1 Blockure) can eliminate these complaints for a long period of 7 days.

## THE FIRST AND ONLY CAPD DEVICE IN THE WORLD

We provide service to patients with kidney disorders during the Covid-19 process with the world's first and only CAPD (Continuous Ambulatory Peritoneal Dialysis) device.

With this device which we developed, we made the life of patients and healthcare professionals easier by automating the dialysis process and data recording.



## RAMAN SPECTROSCOPY QUALITATIVE TEST METHOD

FIRST

TIME IN

TURKEY

We are proud to have received the Raman Spectroscopy quantitative test method approval for the first time in Turkey.

With the Raman Spectroscopy quantitative test method, we reduce the test time that takes days to 3 minutes, thus shortening the time for our products to reach patients even more.

## WE ARE THE FASTEST WITH RAPID TEST APPROVAL

We continue to pioneer the firsts with 100% domestic capital in the healthcare sector, which we have been serving for 36 years, and we work with an increasing passion every day.

With the developing technology and scientific studies, alternative test methods are being developed for long-term microbiological analyzes that provide shorter time and reliable results. One of them is the "Sterility Analysis", which is the necessity of sterile products.

With our sterility test method, which we have developed in order to ensure that sterile products, which are of vital importance among hospital products, reach the patient faster; We reduced the sterility test period of our products from 14 days to 5 days.

We continue to pioneer the firsts with 100% domestic capital in the healthcare sector, which we have been serving for 36 years, and we work with an increasing passion every day.





## **PARAMETRIC RELEASE**

In all sterile products, product release does not occur without sterilization tests; You are legally obliged to keep your product in your warehouse for 14 days. If the test is positive, you can get permission to sell the product.

Thanks to this reliability, sterility test is not applied for products with terminal sterilization as the final process stage, and the product is shipped directly without waiting for 14 days.

As, Polifarma, we are proud to announce the start of this application wfor Polifleks 0.9 % Isotonic Sodium Chloride Solution For I.V. Infusion, Polifleks 5% Dextrose Solution For I.V. Infusion, Polifleks Isolene Balanced Electrolyte Solution For I.V. Infusion, Polifleks Lactated Ringer Solution For I.V Infusion, Sterile Distilled Water Irrigation Solution, Isotonic Sodium Chloride Irrigation Solution product which we gained right with the parametric release approval.

## RANKED FIRST IN THE R&D PROJECT MARKET COMPETITION!

Our project "Developing a stable oral solution form of Favipiravirin, which is highly effective against Covid-19, for the first time in the world", which was carried out with great devotion by our Pol R&D unit, was awarded the first place in the "medicine" category among 141 projects.



POLINUTHREE

Turkey's first domestic parenteral nutrition solution was produced in Pol R&D laboratories.



#### THE MOST KNOWN AND PREFERRED BRAND OF HOSPITAL PRODUCTS

According to the results of the research conducted by an indepented research company; we are the most known and preferred brand of hospital products among the officials and employees of public hospitals, university hospitals, private hospitals and pharmaceutical warehouses. This pride belongs to all of us.

We will work harder and achieve more to maintain our leadership and the trust in our brand.

## CORPORATE SOCIAL RESPONSIBILITY PROJECTS





TURKISH EDUCATION ASSOCIATION

### PHA. NECDET NURI KUMRULU SCHOLARSHIP FUND

We continue to actively live our mission of benefit, which we have maintained for 36 years, in all areas of life. We support young people who need financial support in education with the late Pharmacist Necdet Nuri Kumrulu scholarship fund, which we created in cooperation with the Turkish Education Association.

With the "Pharmacist Necdet Nuri Kumrulu Scholarship Fund", we will continue to support our youth, who are the bright side of our future, and to shed light on their path in their education processes.



## SUPPORT TO LÖSEV

Our Licensing Department employees have prepared and delivered packages of clothes-food-goods for thousands of children with leukemia and cancer all over Turkey. There is a lot we can do in the Volunteer Membership, where everyone can support children with leukemia and cancer, whether young or old, male or female, working or retired!



## "WE STAND BY LIFE" FOREST

We are growing all of our values that we have embraced for 36 years with the "We Stand By Life Forest", which we have implemented in cooperation with TEMA. We have created a new memory forest with 10 thousand saplings within the scope of combating climate change and erosion for the sustainability of the environment, the planet and the future. Our aim is benefit, our priority is life.



#### THE SPINAL CORD PARALYTICS ASSOCIATION OF TURKEY

#### BLUE BOTTLECAP PROJECT

Support from our employees to the "Twist it for happinness" project of the Turkish Spinal Cord Paralysis Association! We would like to thank our employees for their efforts by preparing the covers they have accumulated for a year and forwarding them to the association today.



ORTHOPEDIC DISABLED ASSOCIATION

## POLIFAYDA COMMUNITY AWARENESS EVENT

At Polifarma, the common purpose of all of us is common benefit for life. This purpose guides us in every step that we take to protect and improve life. That is why the benefit is produced at Polifarma every day for human life and society where we live. Based on our belief in solidarity and assistance; we have prepared 12 wheelchairs together with our team and donated them to the Cyprus Turkish Orthopedic Disabled Association. We stand by life, the benefit for life...

# CERTIFICATES



## GMP CERTIFICATES

SAĞLIK BAKANLIĞI	SAĞLIK BAKANLIĞI	SAĞLIK BAKANLIĞI Türkiye İlaç ve Tibbi Cihaz Kurumu
Türkiye İlaç ve Tibbi Cihaz Kurumu	Vision Buck	tar som tagen tar som tagen
BCMAZRURAN Sertifika No: TR/GMP/2021/66	Bölüm 2	
	Begeri Tibbi Ürünler	2. BEŞERİ TIBBİ ÜRÜNLERDE İTHALAT İŞLEMLERİ
ÜRETİM TESİSİ İYİ İMALAT UYGULAMALARI SERTİFİKASI	1. BEŞERİ TIBBİ ÜRÜN ÜRETİM FAALİYETLERİ	2.1 Ithal Tabbi Ürünlerin Kalite Kontrol Testleri
üm 1	Öretici eğer öcel parkar gerektiren tirtinleri tiretiyer ite kişili tirtin işin te doci formu bölümlerin alında belimtineldir (teneğin radyofarmasitikler veya penistin, süftmanid, süccaksikler, sofalosporinler, kornomal	2.1.4 Biyolojik 2.2 İthal Tibbi Ürünlerin Seri Serbest Barakalması
sertifika 1262 sayılı İspençiyari ve Tibbi Müstahzarlar Karamu ile Beşeri Tibbi Örünler	aktivite äränleri veya diger potantiyel tehlikeli aktif maddeler içeren äränler)	2.2.3 Bivoloik Tébi Ürüzler
athaneleri Yönetmeliği* ve güncel İyi İmalat Uygulamaları Kılavuzu gereklilikleri doğrulturanda kleştirilen denetim somacu dizenlenmiştir. Söz komusu mevzuat Avrapa Birliği Direktifleriyle ve		213.2 Institutioja Urinter Bu sertifikanın kapsamı ile ilgili sınırlamalar veya açıklayıcı yorumlar:
asötök Denetim İşbirliği Konvansiyonu (PJC/s) gereklilikleriyle uyumludur.	L.1.2.1 Bioyth Hercenti Senter     -Kandyepinji çüzeldisi     -Mesan vekana çolatibii	<ul> <li>2.1.4 "CoronaVac 600SU/0,5ml IM Enjeksiyonluk Sinpansiyon içeren Flakon ve CoronaVac 600SU/0,5ml IM Enjeksiyonluk Sinpansiyon içeren Kullanıma Hazır Enjektör" ürünleri seri kontrol</li> </ul>
iye Îlaç ve Tibbi Cîhaz Kurumu üreticiye ait aşağıdaki bilgileri onaylar:	-Inflayoshik çizetin -Perkonal divaliz çizetini	analizieri için geçerlidir. - 2.2.3.2 "CoronaVac 600SU/0,5ml IM Enjeksiyonluk Süspansiyon içeren Flakon ve CoronaVac
icinin Unvana : POLIFARMA ILAÇ SAN. VE TİC. A.Ş.	-Yukama çüretkini İnfirmatiki amilikinen	600SU0,5ml IM Enjeksiyonlak Slopansiyon içerem Kullanırma Hazır Enjeksle" ürünleri için seri kontrol azalizlerini içeren seri serbest buskma faaliyetleri için geçerlidir.
kez/Yazışma Adresi : Vakıflar OSB Mah. Sanayi Cad. No.22/1 Ergene/Tekirdağ s Adresi : Vakıflar OSB Mah. Sanayi Cad. No.22/1 Ergene/Tekirdağ	1.1.2.3 Kitglik Blacindi Smlar - Epidolymolik imflaynolik emilikyon 1.1.3 Sexi uterku berakma	
im Yeri kin Belgesi Tarihi : 09.03.2021 im Yeri kin Belgesi Sayss : TR/CY/2019/11-7	1.1.3 Seri serbest brakesa 1.2 Steril Olmayan Ürünler	Sertifikanın geçerlilik süresi 03/02/2021 tarihli ve E-24931227-020-3664 sayılı Makam Oluru doğrultusunda uzatılmış olup, işbu sertifika 31/12/2021 tarihine kadar geçerlidir.
savılı İspençiyari ve Tibbi Müstahgarlar Kananu ile Beseri Tibbi Örünler İmalathaneleri	1.2.1 Steril Otmayan Urtinler (apagodaki dozaj formlan için iplemler yürütülür) 1.2.1.5 Hasio i Läzler	11.03.2021 TR/GMP/2021/66
etneliği ve gäncel hı İmalat Uygulamaları Kılavuzu gereklilikleri doğruftusunda denetlenmiştir.	-Soluma çürelini 1.2.2 Seri serbent bırakma	
5/10/2018, tarihånde gerçekleştirilen en son denetime göre äretim yerinin GMP kaşullarına uygun ha anlaşılmıştır.		Ferhat GÜNGÖR
p məşənəşər. artifika üretim yerinin denetim sırasındaki durumunu belirtir ve denetim tarihi üzerinden 3 yıl	1.3.2 Seri serbest burakma iglemleri 1.3.2 Immitoolgi Dinkier 1.3.26 Immitoolgi Dinkier	Kurum Başkan Yardımcısı
is ise üretim yerinin GMP uygunluğu konusunda Türkiye İlaç ve Tıbbi Cihaz Kurumu'na	1.5 Ambalailama	$\cap$
almalıdır. Ancak sertifikanın geçerlilik sücesinin risk bazlı değerlendirmeler sonucunda uzətılması kəsaltılması darumunda kısırlamalar veya açıklamalar kəsmında bu darum belirtilir.	1.6 Kalite Kontrol Testleri	
ertifika Bölüm 1 ve Bölüm 2 ile birlikte tüm savfaların ibraz edilmesi darumanda recerlidir.	1.6.1 Mikrobiyolojik (steril) 1.6.2 Mikrobiyolojik (steril olmsyan)	
p edilmesi halinde bu sertifika Türkiye İlaç ve Tıbbi Cihaz Kurursu tarafından doğrulanabilir.	1.6.3 Kinyusal/Kirikael 1.6.4 Biyolojik	1
upa Birliğinin 2003/94/AT sayılı Beşeri Tübbi Örünler İçin İyi İmalat Uyçulamaları İhteleri ve Kılanıcu	Bu sertifikanın kapsanı ile ilgili sınırlamalar veya açıklayscı yorumlar:	the ise Table Church
ndaki direktifi ile 2001/83/EC sayılı beşeri töbli təsinlər hakkındaki direktifine paraleldir.	<ul> <li>- 1.1.2.1: PVC torba, polipropilen torba, cam sige, polipropilen jage ve alimnisyum sige jein geoerlidir.</li> <li>- 1.1.3: "Polifielas '90.9 Insteak Sodyam Klereir I.V. Inflayon sign Gozelli", "Polifielas '950 Delestroz Sodaki I.V. Inflayon bin Cozelli", "Polifielas Latesta Kinger I.V. Inflayona lein Cozelli" ("PP Torba) ve</li> </ul>	
	"Polifieks Izolen Denecii Elektrolit I.V. Infizyon Icin Cözelti" (PP Torba) isimli ürlinler icin parametrik	
	serbest baskma faaliyetise izia verilmesi uygan bulunmuştar. . 1.3.2.2 "CromaVus 6605U.0.5ml IM Enjeksiyonluk Sispansiyon içeren Flakon ve CoronaVac 6005U/0.5ml IM Enjeksiyonluk Sispansiyon içeren Kallanma Hazar Enjektle" ürinleri için seri	
	kontrol analizierini joeren seri serbest barakma faalivetleri join gecerlidir.	
0	<ul> <li>1.6.4 "CoronaVac 600SU/0,5ml IM Enjeksiyonluk Süspansiyon içeren Flakon ve CoronaVac 600SU/0,5ml IM Enjeksiyonluk Süspansiyon içeren Kullarıma-Hazır Enjektör" ürünleri seri kontrol</li> </ul>	
hand	analizieri için geçerlidir.	
3MP/2021/66 Ferhat GÜNGÖR	TR/GMP/2021/66 Contact GCNOOR	
Kurum Başkan Yardımcısa	Kuram Başkan Yardımcısı	
Adres: Sögötüzü Mahallesi 2176. Sok. No.5 06520 Çankaya/ANKARA Tel: (0312) 218 30 00 Fax: (0312) 218 34 60	Adres: Söğütözü Mahallesi 2176: Sok. No:5 06520 Çankaya/ANKARA Tel: (0312) 218 30 00 Fas: (0312) 218 34 60	Adres: Söğlötük Mahallesi 2176. Sok. No:5 06520 Çankaya/ANKARA Tel: (0312) 218 30 00 Fax: (0312) 218 34 60
1/3	2/3	3/3

T	РЕПУБЛИКА БЪЛГАРИЯ Изпълнителна агенция по лекарствата REPUBLIC OF BULGARIA Bulgarian Drug Agency
	CEPTUФИКАТ ЗА ДОБРА ПРОИЗВОДСТВЕНА ПРАКТИКА CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER
	3h BG/GMP/2021/191
	Hacr 1 Part 1
чл. 111, ал. 5	зултат на извършена проверка на производител на лекарствени продукти съгласи от Директива 2001/83/EC или чл. 15 от Директива 2001/20/EC*. 5 on impection in accordance with Art. 111(5) of Directive 2001/83/EC or Art. 15 of Directive
Изпълнители Bulgarian Drug	на агенция по лекарствата на Република България удостоверява следното: Agency confirms the following:
	лят на лекарствени продукти:
	ç San. Ve Tic A.S.
Адрес на обен Site address:	cra:
Vakiflar OSB	Mahallesi, Sanayi Caddesi, No: 22/1, Ergene, Tekirdağ, Republic of Turkey във връзка с разрешение за употреба, на лекарствени продукти, произведени извъл
of Bulgaria Art.2	269(4) of Medicinal Products for Human Use Act.
При последнат производство о	га проверка на дружеството, проведена на 29/10/2021 бе установено, че условията на са в съответствие с прицините и изискванията за добра произволствена практика
производство посочени в Ди From the knowled considered that I	та проверка на дружеството, проведена на 29/10/2021 бе установено, че условнята н са н съответствие с принципите и изнекванията за добра производствена практика регитав 2033/REG. По практави (Interpreting of this manufacturer, the latest of which was conducted and 20/10/2021, it i с comflue with principles and guidelines of Good Manufacturer practice lad an in Direction
производство и посочени в Ди, From the knowlead considered that I 2003/94/ЕС/. Настоящият са посочена по-т производителя този срок на 1 което се посочи	case octoretermine competenzamente e introcusamente si audoja aposistanzirionia apartarea percinara 2003/02/02/02/02/02/02/02/02/02/02/02/02/02/
производство о посочени в Диц From the knowled considered that i 2003/94/EC/. Настоящият се производителя този срок на 1 което се посочи This certificate re relied upon to re However, this per- the Restrictions or	can be conserver that comparison that is a subject to a possible constrained approximal $A(D)A(D)$ is the possible constraint of a $D(D)A(D)$ is the complexity of the large dividual is an endoated on $D(D)A(D)A(D)$ is a complexity of the sub-possible constraints of a $D(D)A(D)A(D)$ is a complexity of the large dividual is a subsequence of the large dividual is a subsequence of the possible constraints of a $D(D)A(D)A(D)$ is a subsequence of the large dividual is a subsequence of the possible constraints of the large dividual is a subsequence of the possible of the large dividual is a subsequence of the possible of the large dividual is a subsequence of the possible of the large dividual is a subsequence of the possible of the large dividual is a subsequence of the large dis subsequence
производство посочени в Ди From the knowled considered that I 2003/94/EC/. Настоящият са посочена по производитсяя този срок на и което се посочи This certificate re relied upon to re relied upon to re relied upon to re this certificate re the Restrictions or Ceprudpusarts.	case or conservences on publications or managements and adding and analysis of the second adding and adding add
производство посочени в Ди, From the knowlea considered that I 2003/94/EC. Настоящият се производителя този срок на в което се посочи This certificate re relied upon to re kowever, this per- the Restrictions or Ceptuehusartar This certificate is u Истинността и Съръджене се се н	cas a conserverment e принялитите и износявляюта за добра производствона практики пречитава 2003/2004/2004 chi his manufacturor dise latest of which was conducted on 2010/2012, 1, die galand lange happenbild of dise manufacturor dise latest of which was complex un his production of galaxies and a solution of the solution of the solution of products of passing and complex of the solution of the solution of the solution of a solution of the solution of the solution of the solution of the solution of a solution of the solution of the solution of the solution of the solution is not can solution of the solution of the solution of the solution of the solution of a solution of the solution of the solution of the solution of the solution of the solution offects the solution of the solution of the solution of the solution of the solution of the solution offects the solution of the
проязводство посочени в Ди From the knowled considered that b 2003/94/EC. Инастояният си посочена по- производителя този срок на з което се посочи This cortificate re Koetro се посочи This cortificate re However, this per- file autonico for the Restrictions or Ceptubusata This cortificate as Unconnection of the Connection of the content of the authenticity of the authenticity	es ne corretermente en puntemmitre ne minecimantente su adofes angonismosterinen a masarizza prestima 2003.024% C.D. estis anomicalmente rela istata eficiales nu conducted an 2010/17021/1, 1 de completa sub processo de guidettes el Good Mandpatering Prestice laid donne in Directo estis en en production a consecutar na assectara na aspostenascerare no ne puese un proce- perse in en typica da as ce cueras, ve organisma adecimienta processo de la cuera estis en estis en estis estis a consecutara aspectara estis estis estis estis estis estis estis estis estis manantenes estis estis estis estis estis estis estis estis estis estis estis estis estis estis estis estis nanantenes estis estis estis estis estis estis estis estis estis estis estis estis estis estis estis de la cuera de las manafacteras estis estis estis estis estis estis estis de las de las impectantes estis estis estis estis estis estis estis estis estis estis estis estis de la de la impectante estis estis estis estis estis estis estis estis estis estis estis estis estis de la de la impectante estis estis estis estis estis estis estis estis estis estis estis estis estis de la de la dela impectante estas estis estis estis estis estis estis estis estis estis estis estis de la dela dela impectante estas estis estis estis estis estis estis estis estis estis estis estis estis de la dela dela impectante estas estis


	AYVANCILIK BAKANLIĞI GENEL MÜDÜRLÜĞÜ
	N ÜRETİCİLERİ İÇİN
Settifika No/Certificate No : GMP/TR/V/YÌ/S0152/20 Oretici/The manufacturer : POLIFARMA ÌLAÇ SA?	
Uretin yeri adresi/Site address : Vaktflar OSB Mahallesi,	
Balan-J Yanash Shinam Berlin yu Wanciser Tabli Dinter. Hakhani. Yuzenninjin 23. Maddesi gongli domicarning. Shinama Milling Manashi Milling Mang Shinama Shinama Mang Mang Mang Shinama Shinama Mang	The summarian of the hard book methods and book of the second sec
	Minister SNAN Greet Middle N. Acting Director General Acting Director Conservation States (2019) 2019 (2019) 2019

## GMP CERTIFICATES










## GMP CERTIFICATES





Republic of ye Ministry of Health and Po apreme Board of Drugs & Media Registration Managem	al Appliances	بالأكريك ( تُركينك ) ارد المحمدة العامية والسكان الطبا للأدوية والمستزمات الطبية إدراة التسجيل	e
	Pharmaceutical Product Company     Medical Appliances Company		
The Technical Commi	To The Following Da Dawa Pharma	Re-Registration Of The Company Accordiata. بيانات الواسح الفائية للتسجيل Reg.Committee Meeting Dat	
Adress of Local Agent	ress of Local Agent Sana'a		1000
عنوان الوكيل Manufacturer عشركة المنتجد Company Name		منعاء Date 18/02/2018 التنبيع Polifarma ILac San. Ve Tic. A.S.	
Country of Origin(النشا) Address (المنوان)	ry of Origin(بلد المانية) Turkey		
و التسجيل)،Registration No	رقاریخ التسجیلی) Registration Date (تاریخ التسجیل) 18/02/2018	Expire Registration Date(رمخ انتماء التسجيل) 17/02/2023	<b>3</b> )
Accepted Production Lines کوشاوط الکیونک	General Sterile Products:     Large Volume Parenteral (X)     Gias Bottle.     PP Bottle, PP Bags.     PV CBags.     Small Volume Parenteral (S)     (Ampules, Vials).	P):	5
Marketing Authorization		الهيئة العليا للأدوية	
الشركة المدوقة ( Holder Name د الشما ) Country of Origin			_

## ISO CERTIFICATES



for the management system according to ISO 8001:2015 and ISO 14001:2015 and ISO 45001:201	for the manag	amont evetom a	aarding
turnished and in accordance with certification procedure it is certified to the company of the c	to ISO 9001:2	015 and ISO 1400	
Variance of the second	furnished and in ac	conforming application cordance with certification	n with the regulation was on procedure it is certified for
Design, manufacturing and distribution of large volume parenteral solution.         Unit in the solution of large volume in the solution.           Centrate Regenzation Net:         10 19 100 19040 10 19 1020 2000         Valid unit: 2025-06-04 2000 2000           Audi Report Net:         3330 2MMB J0           The solution regels unrefered the incodence with the Tic Lasting and centration procedures and the destination sector and the solution of the centration sector and the centration sector and the solution of the centration procedures and the centration sector and the solution of the centration sector and the centration sector and the centration of the centration procedures and the centration sector and the centration sector and the centration procedure and the centration sector and the centration of the centration of the centration sector and the centration sector and the centration of the centration sector and the centration sector and the centration of the centration sector and the centration sector and the centration of the centration sector and the centration sector and the centration of the centration sector and the centration sector and the centration of the centration sector and the centration sector and the centration of the centration sector and the centration sector and the centration sector and the centration of the centration sector and the centration sector and the centration sector and the centration of the centration sector and the centration sector and the centration sector and the centration of the centration sector and the centration sector and the centration sector and the centration sector and the centration sector and the centration sector and the centration sector and the centration sector and the centration sector and the centration sector and the centration sector and the centration second the centration sector and the centration sector and the cen	POLIFARMA	Vakıflar OSB Mahalles	i Sanayi Caddesi No: 22/1
parenteral solution.         TC 5 100 19666         Valid unit: 2025-06-04           Centrace Regenzation Na:         TC 5 10 19247         Valid unit: 2025-06-04           TO 5 10 20247         Valid tom: 2025-06-04         Valid tom: 2025-06-04           Audit Report No:         330 30 MMB-J0         To 5 10 1924         Valid tom: 2025-06-04           To september of the contraction of the contraction procedures and the centraction sector and the the TC building and centraction procedures and the centraction sector and the the TC building and centraction procedures and the centraction sector and the the TC building and centraction procedures and the centraction sector and the the TC building and centraction procedures and the centraction sector and the the TC building and centraction procedures and the centraction sector and the the TC building and centraction procedures and the centraction sector and the the the the the the the the the the	Scope:		
Centificate Registration No:         10 15 100 151005         Valid unit: 2029-06-04           TO 15 112 2024         Valid unit: 2029-06-04           Audit Report No:         330 20 MMB J0           To the integration of the integrates			on of large volume
This sufficient net constantial discontance with the TIC auditing and certification procedures and backpet to require weakness audit. The transmission of the TIC auditing and certification procedures and the transmission of	Certificate Registration I	No.: TIC 15 104 131085	
is subject to regular surveillance audits.	Audit Report No.:	3330 2MMB J0	
TÜV Thüringen e.V. Certification body for THÜRINGEN	This certification was condu is subject to regular surveil	acted in accordance with the TIC au ance audits.	diting and certification procedures and
systems and personnel			Jena, 2022-05-23
CORES DALKS DALWARD DA		Destable Askediter unpublik D-2he 198006-05-02	





®	
TSE has issued an IQNet recognized certificate that the organization: POLIFARMA ILAÇ SANAYİ VE TİCARET A.Ş.	
VAOFLAR OSB MAH, SAANYI CAD, NO.2211 ERCENT TEORIDAO'I (TORKYE haa nejwarnota and mankakia e CUSTOMER BATEFACTION MANAGAMENT FYSTEM which Will be requiremeds of the dowing databad	
TS ISO 10002:2018	
Issued on: 01-06-2022 Expires on: 31-05-2025	
The attention is denote likely the ISBN Prove's signal contracts and control to used as a state-denote convert. Registration Number : TR-MY-IST-6/22	
-IONet - Hatter Alex Stoichitoin President of IQNet - Istanbul Certification Manager	
LINE CONF. The second	200001-4710-
100	count of the

## MEDICAL DEVICE CERTIFICATES

kiwa		kiwa
<section-header><section-header><section-header><section-header><text><text><text><text><text><text><text><text><text><text><text></text></text></text></text></text></text></text></text></text></text></text></section-header></section-header></section-header></section-header>	CERTIFICATE	Internet of the Controlline         Page 1/L           Ind Caunify Automatic Systems activity of Caunify Caunify Automatic Systems activity of Caunify Caunify Automatic Systems activity of Caunify Caunify Automatic Systems activity of Caunify Automatic Systems actintereactivity of Caunify Automatic Systematic Syste
New Belgehandness Honselent A.S. 1008 S Cast No. 11 Nussian, Nussian Tankay Nussian S Cast No. 11 Nussian, Nussian Tankay Nussian, Nussian, Nussian S Nussian, Nussian Nussian, Nus		Ken Beigelandime Hissenfeld A.S. 1938 S. Call Mit 19 Feadown, Yuak Marcad, Fulwy Set. 49 27 95 32 57 P. (Ke. 49 27 95 1812 27 N 1969 www.san.ord) + endl produgidame.com Y








## TRADEMARK REGISTRATION CERTIFICATES













## POLIFARMA "We stand by life"

#### **Production Facility**

Vakıflar OSB Mah. Sanayi Cad. No: 22/1 P.K.: 59930 Ergene / Tekirdağ Telephone: 0282 675 14 04 Fax: 0282 675 14 05 E-Mail: info@polifarma.com.tr

#### Headquarters

Halkali Merkez Mah. Basin Ekspres Cad. Capital Tower İş Merkezi, No: 9 Kat: 6 Halkalı Küçükçekmece / Istanbul PK: 34259 Telephone: 0212 481 00 13 Fax: 0212 481 00 73 E-mail: info@polifarma.com.tr

#### **Regulatory Center**

312 VISTA Eskişehir Yolu 2176. Cadde No:9 Kat:7 Ofis No:14 Söğütözü – ANKARA / TÜRKİYE Telephone: 0312 287 18 89 Fax: 0312 287 64 49 E-mail: info@polifarma.com.tr